# Georgia Newborn Screening

## **Policy and Procedure Manual**





The purpose of this manual is to provide a structured and informative framework for the establishment and operation of the Georgia Newborn Screening (NBS) Program to help ensure the health and well-being of every newborn in the state. The manual provides information and tools for healthcare professionals and stakeholders to conduct newborn screening effectively and efficiently for early detection and intervention of congenital disorders and inherited conditions in infants.

The NBS Program is committed to the following key objectives:

**Universal Access:** Every Georgia infant receives quality and timely newborn screening for the disorders mandated by state regulations.

**Follow-up and Recommendations:** Newborns with abnormal screening test results receive timely and appropriate follow-up. These results and recommendations are shared with healthcare providers to expedite diagnostic and treatment services.

**Data for Action:** Robust data collection, analysis, and dissemination inform all aspects of the program's operations. This includes the assessment of newborn screening methods and strategies, cost-effectiveness analyses, and evaluations of health outcomes.

**Parent Education:** Parents and caregivers are empowered with information about the importance of newborn screening and the benefits it offers to Georgia's newborns.

**Technical Assistance and Education:** The NBS Program's diverse range of stakeholders, including birthing facilities, follow-up programs, healthcare professionals, families of affected children, and the public will have the information they need to ensure the early detection and intervention for congenital disorders and inherited conditions in infants.

If you have any questions about the information in this manual, please email <u>DPH-NBS@dph.ga.gov</u>.

## TABLE OF CONTENTS

Table of Contents	3
Section I. Introduction to Newborn Screening	5
1.1 Georgia Newborn Screening Program Overview	5
1.2 Newborn Screening Program Contact Information	5
Section 2: Responsibilities in the Newborn Screening Process	6
2.1 Birthing Facility (Specimen Submitter)	6
2.2 Georgia Public Health Laboratory	7
2.3 Newborn Screening Follow-Up Programs	7
2.4 Primary Care Providers	8
Section 3: Accessing Newborn Screening Results	9
3.1 Physicians	9
3.2 Parents/Guardians	9
Section 4: Filling Out the Newborn Screening Card	10
4.1 Importance of Complete Demographic Information on the Newborn Screening Card	10
4.2 Guidance for Completing the Newborn Screening Card	10
Section 5: Collecting, Handling, and Shipping Newborn Screening Cards	15
5.1 Timing of Dried Blood Spot Specimen Collection	15
5.2 Dried Blood Spot Specimen Collection Procedures	15
5.3 Newborn Screening Card Drying, Handling, and Shipping	16
5.4 Metabolic and Endocrine Screening Considerations and NBS Dried Blood Spot Collection Schedules for Special Population	ulations
	17
Section 6: Preventing Submission of Newborn Screening Cards That are Unsatisfactory for Testing	19
6.1 Requirements for Newborn Screening Card Accentability for Testing	10
6.2 Categories of Unsatisfactory Results	20
6.3 Correcting an Unsatisfactory Newborn Screening Card	
Section 7: Critical Congenital Heart Disease (CCHD) Screening	
7.1 CCHD Overview	22
7.2 CCHD Screening Policies and Procedures	23
7.3 Abnormal CCHD Results	
7.4 CCHD Reporting Requirements	
7.5 CCHD in Special Populations	27
Section 8: Newborn Hearing Screening	27
8.1 Newborn Hearing Screening Overview	27
8.2 Newborn Hearing Screening Policies and Procedures	28
8.3 Newborn Hearing Screening Results	29
8.4 Newborn Hearing Screening Reporting Methods and Requirements	
8.5 Newborn Hearing Screening in Special Populations	31
Section 9: Follow-up Program Procedures	
9.1 Metabolic Conditions Follow-Up	32
9.2 Hemoglobin Conditions Follow-Up	32
9.3 Newborn Hearing Screening Follow-Up	35
9.4 Follow-Up Program Contact Information	35
Section 10: Appendices and References	
10.1 Appendices	
Appendix A: Glossary of Terms	
Appendix B: Georgia Rules and Regulations Pertaining to Newborn Screening	
Appendix C: Newborn Screening Panel and Disorder-Specific Information	

Appendix D: Parent/Guardian Refusal of Newborn Screening	41
Appendix E: Declaration of Religious Objection to Newborn Screening Form	42
Appendix F: Georgia Newborn Screening Program Policy for Retention and Use of Residual Dried Blood Spot (DBS) Specim	ens43
Appendix G: Training and Educational Resources	46
Appendix H: e-Reports Web Portal Registration Form	51
Appendix I: Authorization for Release of Newborn Screening Report Form	52
Appendix J: NBS Delayed Screening Report Form	53
Appendix K: Instructions for Selecting Hearing Screening Reporting Method	54
Appendix L: Form to Order Newborn Screen Collection Forms (Georgia Public Health Laboratory) Specimen Collection Out	fit
Order Form	56
Appendix M: Authorization for Release of Protected Health Information	57
Appendix N: Newborn Hearing Screening Results and Recommendations Form	58
Appendix O: Newborn Screen correction Form	59
Appendix O: Newborn Screen correction Form Appendix P: Newborn Screening Panel History	59 60
Appendix O: Newborn Screen correction Form Appendix P: Newborn Screening Panel History 10.2 References	59 60 61

## SECTION I. INTRODUCTION TO NEWBORN SCREENING

Newborn Screening (NBS) is a public health activity aimed at early identification of conditions in infants that, without prompt detection and treatment, can result in permanent disability or death. NBS programs have saved countless lives by identifying infants with rare but serious health conditions shortly after birth. Over the years, these programs have evolved, expanding the list of screened disorders and incorporating advances in technology and medical knowledge.

Effective newborn screening involves hospitals, state newborn screening laboratories, primary care providers, follow-up programs, parents, and community agencies. Healthcare providers are on the frontline ensuring all newborns get the screenings they need and receive timely and appropriate follow-up care.

## 1.1 GEORGIA NEWBORN SCREENING PROGRAM OVERVIEW

Georgia's NBS Program is a state-mandated program within the Georgia Department of Public Health's (DPH) Public Health Laboratory and Division of Women, Children, and Nursing Services, Office of Child Health. The NBS Program in Georgia operates as a universal access, coordinated, multi-partner system dedicated to the early identification and intervention of congenital and heritable conditions through efficient screening, followup, consultation, tracking, data analysis, and educational initiatives.

The NBS Program includes 3 categories of health screens:

- **Metabolic and endocrine conditions:** Blood spots are collected for laboratory testing for selected endocrine and genetic metabolic conditions.
- Critical Congenital Heart Disease (CCHD): Pulse oximetry measures are collected to detect CCHD.
- **Congenital Hearing Loss:** Auditory measurements are collected to detect congenital hearing loss.

The Georgia Public Health Laboratory provides accurate and timely genetic testing on dried blood spots collected from all newborns in Georgia. Currently, the Georgia Public Health Laboratory conducts testing for and reports results for metabolic and endocrine conditions for approximately 125,000 Georgia newborns every year.

# 1.2 NEWBORN SCREENING PROGRAM CONTACT INFORMATION

General Program Questions, Order Educational Brochures, or Training Resource Needs: Georgia Newborn Screening Program: Email: <u>DPH-NBS@dph.ga.gov</u> Fax: (404) 657-2773 Webpage: www.dph.ga.gov/NBS

## Laboratory-Specific Questions or to Order Newborn Screening Cards:

**Georgia Public Health Laboratory:** The Newborn Screening Section Georgia Public Health Laboratory 1749 Clairmont Road Decatur, GA 30033-4050 Phone: (404) 327-7950 Fax: (404) 327-7919 Webpage: www.dph.ga.gov/lab

## SECTION 2: RESPONSIBILITIES IN THE NEWBORN SCREENING PROCESS

The NBS process is a coordinated effort between the birthing facility (specimen submitter), primary care physician, Georgia Public Health Laboratory, and the NBS Follow-Up program.

## 2.1 BIRTHING FACILITY (SPECIMEN SUBMITTER)

It is the responsibility of the birthing facility, birthing center, physician's office, or other healthcare facility in which each infant is born to ensure that a newborn screening dried blood spot (NBS DBS) specimen is collected and submitted to the Georgia Public Health Laboratory for testing for select endocrine and genetic metabolic conditions. Testing for congenital hearing loss and CCHD must also be completed, and results (1) recorded in the clinical record, (2) reported to DPH, and (3) shared with the infant's parent or guardian. Newborns who have already received an echocardiogram for any reason may be excluded from CCHD screening.

If the birth occurs outside a birthing facility, birthing center, or other healthcare facility, then it is the responsibility of the attending physician or midwife to properly complete NBS DBS specimen collection and submit the NBS DBS card to Georgia Public Health Laboratory. When a live birth occurs in any hospital, birthing center, or facility that is equipped to conduct the newborn hearing screening and Critical Congenital Heart Disease (CCHD) screening, those tests shall be conducted prior to the infant's discharge.

#### Newborn Dried Blood Spot Specimen Card:

Submitters are responsible for ensuring all the fields on the NBS DBS card are completed before it is sent to Georgia Public Health Laboratory. See <u>Section 5</u> for more information. The birthing facility is responsible for the recollection of specimens in the event of specimens lost in transit or submission of specimens that are inadequate for testing.

#### Critical Congenital Heart Disease (CCHD) and Congenital Hearing Loss Screening:

The results of the test shall be included in the baby's clinical record, reported to the Georgia Department of Public Health, and given to the parents or legal guardians, along with any follow-up recommendations.

#### Providing Information on Newborn Screening to Parents:

The birthing facility, birthing center, or other healthcare facility in which the infant is born is responsible for ensuring parents are given a copy of "Georgia Newborn Screening Program: What Every Parent Should Know." DPH offers free brochures that will be shipped to the submitting facility quarterly. Email <u>DPH-NBS@dph.ga.gov</u> to place an order.

All CCHD and Hearing Screening results must be given to the parents or legal guardians along with any followup recommendations.

#### Re-collection of NBS DBS Specimens with Unsatisfactory Results:

Submitting a specimen that is inadequate for testing leads to delays in providing results and places the newborn at risk for a delayed diagnosis. Birthing facilities must collect a second specimen if the first specimen submitted to the Georgia Public Health Laboratory was determined to be unsatisfactory for testing. The second specimen should be collected as soon as possible. It should be collected with another NBS DBS card and sent to the Georgia Public Health Laboratory. If the infant has been discharged, the birthing facility shall be responsible for contacting the pediatrician listed on the NBS DBS card or the infant's parent or legal guardian if the pediatrician's information is missing to arrange for the collection of a second specimen.

## 2.2 GEORGIA PUBLIC HEALTH LABORATORY

The Georgia Public Health Laboratory is responsible for receiving dried blood spot specimens and conducting laboratory testing. The Georgia Public Health Laboratory sends a written report of newborn screening results to the submitter and pediatrician listed on the NBS DBS card. Abnormal results are also reported by the Laboratory to the designated follow-up program.

## 2.3 NEWBORN SCREENING FOLLOW-UP PROGRAMS

Timely follow-up of an abnormal result is critical to preventing morbidity and mortality. State-designated follow-up programs locate infants with abnormal screening results, provide education to their parents/guardians, and facilitate referrals for diagnostic testing and disease management in a timely fashion.

DPH contracts with the following organizations to assist with timely follow-up:

- Emory University Department of Human Genetics Follow-Up Program: Organic Acid Disorders, Fatty Acid Oxidation Disorders, Amino Acid Disorders, Lysosomal Storage Disorders, Endocrine Disorders, and Other Disorders
- Augusta University and Children's Healthcare of Atlanta: Sickle Cell Disease and Hemoglobin Disorders
- Sickle Cell Foundation: Sickle Cell Trait
- Early Hearing Detection and Intervention (EHDI) District Coordinators: Congenital hearing loss

## 2.4 PRIMARY CARE PROVIDERS

The provider listed on the NBS DBS card as the pediatrician after discharge will receive the results of newborn screening for metabolic and endocrine disorders and is responsible for contacting the family to arrange diagnostic testing and follow-up as indicated. If the infant is seeing a different healthcare provider than listed on the NBS DBS card, the family must inform DPH immediately (email <u>DPH-NBS@dph.ga.gov</u>) so the correct provider can be notified.

Birthing hospitals are responsible for informing parents about abnormal screening results for both CCHD and hearing screenings and providing referrals following the abnormal results. Primary care providers (PCP) should confirm receipt of CCHD and hearing testing results with parents and whether the results were abnormal and required referral.

See <u>Section 3: Accessing Newborn Screening Results</u> for more information regarding accessing newborn screening results.

#### Coordination with Follow-Up Programs:

The PCP will be contacted by the relevant state-designated follow-up programs about infants with abnormal newborn screening results:

- 1. **Emory University Department of Human Genetics Follow-Up Program:** Organic Acid Disorders, Fatty Acid Oxidation Disorders, Amino Acid Disorders, Lysosomal Storage Disorders, Endocrine Disorders, and Other Disorders
- 2. Augusta University, Children's Healthcare of Atlanta, and The Sickle Cell Foundation of Georgia: Sickle Cell Disease Follow-Up
- 3. District Early Hearing Detection and Intervention Coordinator: Hearing screening follow-up

The PCP will provide the family with the NBS results and education. The PCP may be asked by a statedesignated follow-up program to do one or more of the following:

- 1. **Contact the family to bring the infant in for an assessment**. Infants should be assessed as soon as possible. The follow-up program may advise that an immediate assessment or referral to an emergency department is necessary for some infants.
- 2. **Repeat the newborn screen -** Many infants will need a repeat screen to confirm a diagnosis. The follow-up program will include this request in the verbal and/or faxed report.
- 3. **Collect diagnostic test samples** Some infants will require diagnostic testing. The follow-up team's verbal and faxed report will include information on how to do this, details on which tests to order, and recommended labs.
- 4. **Refer the infant for confirmatory testing** Some infants may need to be referred to a specialist for additional testing to confirm a diagnosis. The follow-up program will provide this guidance to the PCP.

Primary care providers confirming abnormal test results or clinical symptoms for the conditions listed in DPH Rule 511-5-5-.03 must report those findings to the appropriate follow-up provider. See <u>Section 9: Follow-Up</u> <u>Program Procedures</u> and <u>Appendix B: Georgia Rules and Regulations Pertaining to Newborn Screening</u>.

## SECTION 3: ACCESSING NEWBORN SCREENING RESULTS

### 3.1 PHYSICIANS

Physicians have two options for obtaining newborn screening results, as outlined below. Results are typically populated in the following databases approximately 7-10 days after birth.

- e-Reports: Online Portal for physicians registered in Georgia to retrieve newborn screening results. The web portal address is <u>https://ereports.ga.gov/dph/eReports</u>. See eReports Web Portal Registration Form in <u>Appendix H: eReports Web Portal Registration Form</u> for instructions on registration.
  - Note: e-Reports will generate a medical report for conditions tested via NBS DBS card. If an infant is born at a hospital who reports hearing and cardiac screening outside of the DBS card, those results will not be available in e-reports.
- State Electronic Notification Surveillance System (SendSS): Authorized providers can also access newborn screening results online through the <u>State Electronic Notification Surveillance System</u> (<u>SendSS</u>). When registering, request access to "SendSS Newborn: Newborn Screening Results"
  - Note: SendSS generates an **unofficial report** that includes all conditions (i.e., congenital hearing loss, Critical Congenital Heart Disease (CCHD), and metabolic/endocrine disorders.

### 3.2 PARENTS/GUARDIANS

Parents and guardians may request a copy of their child's newborn screening results by e-mail a completed Authorization for Release of Newborn Screening Report <u>form</u> (<u>Appendix I: Authorization for Release of Newborn Screening Report Form</u>) along with proof of identity to <u>DPH-NBS@dph.ga.gov</u>.

## SECTION 4: FILLING OUT THE NEWBORN SCREENING CARD 4.1 IMPORTANCE OF COMPLETE DEMOGRAPHIC INFORMATION ON THE NEWBORN SCREENING CARD

Submitters are responsible for ensuring all the fields on the NBS DBS card are completed before it is sent to the Georgia Public Health Laboratory. All information requested on the NBS DBS card is vital for timely and accurate screening and follow-up. The Georgia Public Health Laboratory relies on the date and time of birth, the date and time of specimen collection, and birth weight recorded on the NBS DBS card to determine whether screening results are normal or abnormal. Omitting this information or providing inaccurate, incomplete, or illegible information may result in inaccurate results, delays in reporting results, or rejection of the specimen and the need for re-collection of the specimen.

Providing the names of the (1) submitting health care provider and (2) pediatrician after discharge on the NBS DBS card is critical for ensuring rapid follow-up of the results. State-designated Follow-up Programs rely on the demographic information provided on the NBS DBS card to locate infants with abnormal results to ensure that they receive timely follow-up.

## 4.2 GUIDANCE FOR COMPLETING THE NEWBORN SCREENING CARD

Newborn screening cards are medical devices. They should be stored in a cool, dry place away from direct sunlight.

The first step in blood spot specimen collection is to check the NBS DBS card's expiration date.

- NBS DBS cards are to be used on or before the expiration date.
- Destroy all outdated cards immediately.
- Newborn screening cards can be ordered from the Georgia Public Health Laboratory by calling (404) 327-7928 or ordering from <u>GPHL</u>. See <u>Appendix L: Form to Order Newborn Screen Collection Forms (Georgia</u> <u>Public Health Laboratory) Specimen Collection Order Form</u>.
- Do not request more than a 6-month supply of cards.

	Submitting Healthcare Provider (Report and Invo	ce to:)	Si	ubmitter Code		
				F	or GA State Lab U	Ise Only
	Submitting Facility's Address	Ch.	Countr	Chris	ZIDCode	Scr 33
	Sheet	City	County	Sale	ZIP Gode	A 30
	S Pediatrician After Discharge		Si	ubmitter Code Pediatrician	n's Phone Number	lewt G
	ICIA			Area Co	de Number )	ry - h
	Pediatrician's Mailing Address (Report Copy To)		J (			rratol L De
Ē	Street	City	County	State	ZIP Code	abo
	Reason for Test     1# Test     Routine Retest     Retest     Chart Number Model	- Prior Unsatisfactory Retest - Prior Ab	normal Parental Refusal	Collection Weight	St Ang (Birth)	ate Lab Use Only Unsat Code: Unsat Code:
	Infant's Last Name	Spital Lau Access No.	(Grams) Birth Date	(Grams) Birth 1	(Weeks)	No Yes Boo
2			Month Day	Year (Milt	ary)	No Yes
1	Infant's First Name	Sex Male Fen	ale Unknown Month	Collection Date Day Year	Collection Time (Military)	Collected By (Initials)
	Single Birth Trans	fusion: Date of Last:	Protein Feed: Breast	Formula	Both	leconium ileus
			Parenteral			
			Nutrition:	Formula Trade Name	9: 	
	Infant's Race: White Black	Asian Pacific Islander/ Ame Native Hawaiian' Alas	kan Native Multiracial	Unknown Hispanic:	Yes	No
	Mother / Guardian Last Name		Mot	ther / Guardian Birth Date	Mother / Guardian or Co	ntact's Number
Ē			Montr	Day Tear	( )	
	Mother / Guardian First Name				Emergency Conta	t Number
Ì	Ш				( )	
	Kother / Guardian Address	Citv	County	State	Zip Code	
Н	HEARING Final Screen Date:	Not Screened:	CCHD Res	ults Date:		
		Delayed/WBN Parental Refu	sal Other: Initial:	Right Hand	Foot	
	aOAE	Delayed/NICU Equipment Delayed/NICU	wn Repeat:	Right Hand	Foot	
	Fail Fail ABR and aOAE	Transfer/Hospital	Final Outco	me: 🗌 Pass 🗌 Fail 🗌	ECHO	
15	STATELABD	ATA ENTRY COR	Referred To	):		

#### Figure 4.1 Georgia Newborn Screening Card Example

**Important:** Check the newborn screening card's expiration date before collecting the specimen. The expiration date is located on the left-side of the newborn screening card.

#### Figure 4.2 Georgia Newborn Screening Card Expiration Date Example

Revvity™ 226	Ahlstrom	LOT 116265 / 30610008	∑ 2029-01-31 IVD	

#### Table 4.1 Georgia Newborn Screening Card Data Fields and Descriptions

SUBMITTER SECTION		
Data Field	Description	
Submitting Healthcare Provider	Name of the facility where the specimen was collected	
(Report and Invoice to)		
Submitter Code	Unique identifier for the facility (three digits/letters)	
Submitting Facility's Address		

Submitting Facility's Street	Street of the Submitting Facility
Submitting Facility's City	City of the Submitting Facility
Submitting Facility's County	County of the Submitting Facility
Submitting Facility's State	State of the Submitting Facility
Submitting Facility's Zip Code	Zip Code of the Submitting Facility
	PEDIATRICIAN SECTION
Data Field	Description
Pediatrician After Discharge	Name of pediatrician given by parent or guardian who will administer care after discharge <b>Note:</b> A final NBS report will be mailed to this provider
Submitter Code	Unique identifier for the pediatrician (i.e., six digits "123456"); Add if known
Pediatrician's Phone Number	Named pediatrician's phone number
Pediatrician's Mailing Address (Report G	Сору То)
Pediatrician's Street	Street of the pediatrician's facility
Pediatrician's City	City of the pediatrician's facility
Pediatrician's County	County of the pediatrician's facility
Pediatrician's State	State of the pediatrician's facility
Pediatrician's Zip Code	Zip code of the pediatrician's facility
	BABY SECTION
Data Field	Description
Reason for Test	
• 1 <sup>st</sup> Test checkbox	Select "1st Test" if this is the initial screen for infant
Routine Retest checkbox	Select "Routine Retest" for infants in NICU
<ul> <li>Retest – Prior Unsatisfactory checkbox</li> </ul>	Select "Retest Prior Unsatisfactory" for unsatisfactory result
<ul> <li>Retest – Prior Abnormal checkbox</li> </ul>	Select "Retest Prior Abnormal" for out-of-range result
Parental Refusal checkbox	Select "Refusal" for parents who refuse NBS DBS screening
Chart Number/Medical Record Number	Place infant's chart number/medical record number here
Birthing facility Lab Access Number	If your birthing facility uses lab access number to log the specimens, lab will place that number here
Birth Weight (grams)	Weight taken at birth used for interpretation of results
Collection Weight (grams)	Current weight at time of collection if the infant is older >7 days

Gestational Age (Birth)	Gestation is determined by a physician or based on the dates of pregnancy. Report gestational age in weeks
NICU	Check "yes" if the infant has been admitted to a Level II or III
	special care nursery. Check "no" if the infant has not been
	admitted to a Level II or III special care nursery
Infant's Last Name	Last name of infant
Birth Date	Enter infant's birthdate (MM/DD/YR)
Birth Time (Military)	Infant's time of birth
Adoption	If adopted, check "yes", if not, select "no"
Infant's First Name	Infant's first name. Can be listed as Baby Boy, Baby Girl or if twins:
	Twin A or B if the first name is not known
Sex	Indicate if infant is a male, female or unknown
Collection Date	The date the specimen was collected
Collection Time (Military)	Time the specimen was collected
Collected By (Initials)	The initials of the nurse or lab tech who collected the specimen
Single Birth and Multiple Births	Single birth: If a mother delivered a single infant, check the "Single
	Birth" checkbox
	Multiple birth: If a mother delivered more than one infant, check
	the "Multiple Birth" checkbox, and indicate in what order this infant
	was delivered (e.g., A=1st, B=2nd, C=3rd, D=4 <sup>th</sup> , etc.)
Transfusion	Did the infant have a transfusion? "Yes" or "No"
Date of Last (Transfusion)	If the infant had a transfusion, enter the date of the last transfusion
Protein Feed	Select the infant's current feeding type:
	Breast – breastfed only
	Formula – formula fed only
	<ul> <li>Both – breastfed and formula fed</li> </ul>
Meconium ileus	Select if the infant has a clinical diagnosis of meconium ileus, a bowel obstruction
Parenteral Nutrition	If the infant is currently receiving the administration of nutrients
	intravenously select "ves". If the infant is not currently receiving the
	administration of nutrients intravenously select "no"
Formula Trade Name	If the infant is being fed with formula, enter the formula trade
	name
Infant's Race	Ask parent/guardian, then indicate the race of infant
Hispanic	Select "yes" if the infant's ethnicity is Hispanic. Select "no" if the
	infant's ethnicity is not Hispanic
M	OTHER / GUARDIAN SECTION
Data Field	Description
Mother/ Guardian Last Name	Last name of the birth mother or guardian
Mother/Guardian Birth Date	Birth date of the birth mother or guardian

Mother/Guardian or Contact's Number	Mother's / Guardian's number where she can be best reached after discharge	
Mother/Guardian First Name	Birth mother's or quardian's first name	
Emergency Contact Number	Friend or relative of the mother/guardian who can be contacted if the mother/guardian cannot be reached	
Mother/ Guardian Address		
Mother/ Guardian Street	Residing street of the mother or guardian	
Mother/ Guardian City	Residing city of the mother or guardian	
Mother/ Guardian County	Residing county of the mother or guardian	
Mother/ Guardian State	Residing state of the mother or guardian	
Mother/ Guardian Zip Code	Residing zip code of the mother or guardian	
	HEARING SECTION	
Data Field	Description	
Final Screen Date	Enter the date of the final hearing screen If screened twice, use the date of the second screen	
Right Ear	Select "Pass" if the infant passed the hearing screen in the right ear. Select "Fail" if the infant did not pass the hearing screen in the right ear.	
Left Ear	Select "Pass" if the infant passed the hearing screen in the left ear. Select "Fail" if the infant did not pass the hearing screen in the left ear.	
Screen Method	Check the screening instrument (aABR, aOAE, aABR and aOAE) used for the final hearing screen.	
Not Screened	If the infant did not receive a final screen before the card was submitted indicate the reason: "Delayed/WBN" (well baby nursery), "Parental Refusal", "Delayed/NICU" (neonatal intensive care unit), "Equipment Down", "Other", "Transfer/Birthing facility" (enter the birthing facility name the infant was transferred to).	
CCHD RESULTS SECTION		
Data Field	Description	
Date	Enter the date the CCHD screen was completed	
Initial (Both right hand and either foot r	nust be tested)	
Right Hand	Enter the initial pulse oximetry results (%) for the right hand.	
• Foot	Enter the initial pulse oximetry results (%) for either foot	
Repeat (Both right hand and either foot	must be tested)	
Right Hand	Enter the repeat pulse oximetry results (%) for the right hand.	
• Foot	Enter the repeat pulse oximetry results (%) for either foot	
Final Outcome	Select the appropriate checkbox to indicate the final outcome of CCHD screening.	

	<ul> <li>Select "Pass" if the infant passed the CCHD screening</li> <li>Select "Fail" if the infant did not pass the CCHD screening</li> <li>Select "ECHO" if the infant had an ECHO test completed</li> </ul>
Referred To	Indicate if the infant was referred to a cardiologist or birthing facility. Write the full name of the cardiologist or birthing facility without abbreviations.

## SECTION 5: COLLECTING, HANDLING, AND SHIPPING NEWBORN SCREENING CARDS 5.1 TIMING OF DRIED BLOOD SPOT SPECIMEN

## COLLECTION

A sample of each infant's blood should be collected 24 to 48 hours after first feeding or prior to the infant's discharge from the birthing facility if the infant is discharged before 24 hours of age. It is recommended to collect an NBS DBS specimen from all infants, including those considered unlikely to survive to 24 hours of age.

See <u>Section 5.4</u>: <u>Metabolic and Endocrine Screening Considerations and NBS DBS Collection Schedules</u> for Special Populations for information about the timing of NBS DBS specimen collection from critically ill infants and infants requiring transfusion or total parenteral nutrition.

# 5.2 DRIED BLOOD SPOT SPECIMEN COLLECTION PROCEDURES

Use standard precautions when collecting and handling NBS DBS specimens.

Avoid contamination of NBS DBS cards with physical contaminants such as antiseptic solutions, powders, petroleum jelly, lotions, or other materials, which may adversely affect the testing process.

The NBS DBS specimen collection procedure can be viewed on video by using the link: <u>https://www.youtube.com/watch?v=T-CL7dQRZ7w</u>

Do not use capillary tubes for specimen collection. Capillary tubes contain heparin, which can result in diluted or contaminated NBS DBS specimens.

Check the expiration date prior to performing the heel stick. Every newborn screening card is printed with an expiration date. NBS cards can be used for blood spot collection through the last day of the month of the expiration date printed on the card.

#### **Procedure Steps:**

- 1. Wash hands before collecting the newborn's NBS DBS specimen. Use standard precaution practices (e.g., wear gloves and change gloves between newborns) during specimen collection and handling.
- 2. Fold back the cover sheet on the NBS DBS card to expose the filter paper. Do not touch or handle the preprinted circles on the filter paper before, during, or after applying blood.
- 3. Swaddle the infant or allow the parent to hold the infant to reduce movement and provide comfort.
- 4. Position the infant with feet lower than the level of the heart to improve blood flow.
- 5. Warm the infant's heel by applying a disposable heel-warming device to the area for three to five minutes before beginning the procedure.
- 6. Clean the puncture site with a sterile alcohol pad. Allow to air dry to reduce alcohol which can cause hemolysis and denature of some of the enzymes being tested.
- 7. Use a sterile, single-use, retractable lancet to make an incision in the areas indicated on the diagram on the right.
  - **Average weight infants and older children:** do not exceed puncture depth of 2.0 mm.
  - **Preterm and LBW:** do not exceed a puncture depth of 0.85 mm.
- 8. Wipe away the first drop of blood with dry sterile gauze.
- 9. Allow a large drop of blood to form. To enhance blood flow during

collection, apply gentle intermittent pressure to the heel with the thumb.

NOTE: Do not excessively "milk" or squeeze the puncture site. Milking can cause hemolysis of the specimen or result in a mixture of tissue fluids with the blood specimen, resulting in an unsatisfactory specimen.

- 10. Lightly touch the front (or back) of the filter paper card to the blood drop and fill each printed circle with one single drop, allowing the blood to saturate through completely to the other side of the card.
- 11. Apply blood to one side of the filter paper only. Fill all circle areas. Do not layer successive small drops of blood in the same circle. Avoid touching or smearing the blood spots.
- 12. If blood flow is diminished, repeat steps three through nine with a new sterile lancet.

If there is inadequate blood from the heel to complete specimen collection, alternative methods of collection can be used. Venous, arterial, or umbilical catheter blood may be used. If one of these methods is used, the drops should be applied to the DBS card in a similar manner to the traditional procedure. Allow the blood drop to pool at the tip of the syringe or catheter and apply one drop to the center of the spot.

## 5.3 NEWBORN SCREENING CARD DRYING, HANDLING, AND SHIPPING

Allow the NBS DBS card to thoroughly air dry for at least three hours at an ambient temperature of 18-25°C on a flat, nonabsorbent surface, away from direct heat and sunlight. Do not allow the protective flap to encounter blood spots until the spots are thoroughly dry. Do not stack or allow the blood spots to touch anything during drying.

Avoid contamination of NBS DBS cards with physical contaminants such as antiseptic solutions, powders, petroleum jelly, lotions, or other materials, which may adversely affect the testing process.



After drying, NBS DBS cards should be stored in a cool, dry place. Do not refrigerate.

Send NBS DBS cards to the Georgia Public Health Laboratory within 24 hours of collection.

- Delayed submission to the laboratory may result in a significant delay in the identification of an infant with a disorder.
- Do not accumulate or "batch" specimens before shipping since this may result in specimens too old to test.

#### Send NBS DBS cards to:

Georgia Public Health Laboratory 1749 Clairmont Road Decatur, GA 30033-4053

The Georgia Public Health Laboratory has a contractual agreement with United Parcel Service (UPS) to pick up and transport specimens from birthing facilities in Georgia to the Georgia Public Health Laboratory. Specimens may be shipped using a shipper other than UPS, but the birthing facility or healthcare provider will be responsible for the expense of using a different courier.

The Georgia Public Health Laboratory provides pre-addressed UPS labels specifically for birthing facilities to use to send newborn screening specimens to the Laboratory. The Department of Public Health will pay for one shipment per day per birthing facility for transport of specimens to the Georgia Public Health Laboratory. The Laboratory assumes responsibility for testing only; whoever submits specimens must assume liability for proper identification, collection and prompt delivery of specimens to the State Laboratory.

## 5.4 METABOLIC AND ENDOCRINE SCREENING CONSIDERATIONS AND NBS DRIED BLOOD SPOT COLLECTION SCHEDULES FOR SPECIAL POPULATIONS

There are additional screening considerations and schedules for:

- NICU or Special Care Nurseries
- Transferred Infants
- Transfusions/Blood Products/ECMO
- Low Birth Weight Infants
- Parenteral Nutrition
- NPO/IV Fluids Only
- Older Infants/Children

Multiple screening schedules may apply to an infant, and all relevant schedules described below should be followed.

#### Infants in NICU or Special Care Nurseries

- a) **Upon admission**: Collect the <u>first</u> NBS DBS specimen, regardless of age and weight, and before any other treatments are begun (except respiratory).
- b) **Between 48-72 hours of life**: Collect a <u>second</u> NBS DBS specimen from infants initially screened at < 24 hours of age at first screen.
- c) **At 28 days of life or discharge, whichever comes first**: Collect a <u>third</u> NBS DBS specimen from infants <34 weeks gestational age or <2000 grams at birth.

#### **Transferred Infants**

Birthing facilities transferring an infant to another facility should document in the medical record whether the first newborn screen has been collected. The receiving facility should also note in the medical record whether newborn screening has been done. If it has not been done prior to transfer, the receiving facility should perform a newborn screen upon admission and follow any newborn screening schedules as appropriate to the status and treatment of the transferred infant.

#### Transfusions/Blood Products/ECMO

It is critical to collect a dried blood spot specimen for newborn screening for metabolic and endocrine disorders prior to the first transfusion/ECMO/blood product administration if possible. Even small transfusions can result in inaccurate screening test results. Therefore. a repeat dried blood spot specimen should be collected 120 days after the last receipt of blood product from infants who have received them during the newborn period. By this time, the specimen will no longer contain donor cells that could result in false-negative test results. Please note: This transfusion protocol is only applicable when the DBS schedule is interrupted. If all recommended specimens have been collected according to the appropriate guidelines and no further testing is necessary, please disregard this protocol. Additionally, when submitting specimens, ECMO should be specified as a "transfusion" on the NBS DBS card by facilities when they submit specimens.

#### Low Birth Weight Infants

Low birth weight infants (<2500 grams at birth) who were tested before 24 hours of life should have a screen at 48-72 hours. In infants <34 weeks gestational age or <2000 grams at birth, an additional third screen at 28 days of life or discharge, whichever comes first, is recommended.

If a low-birth-weight infant shows clinical signs consistent with any disorder prior to the scheduled collection of additional screening specimens, confirmatory testing should be done immediately. The state-designated Newborn Screening Follow-Up Programs can be consulted and have on-call specialists available. Refer to <u>Section 9.4: Follow-Up Program Contact Information</u> for information on contacting the Newborn Screening Follow-Up Programs.

Screening at 24-48 hours may result in inaccurate results in some newborns, such as elevated 17hydroxyprogesterone (17-OHP) levels in premature infants and reduced thyroxine (T4) in some cases, which can cause false positives for certain conditions like congenital adrenal hyperplasia and hypothyroidism. These transient imbalances in hormone levels can affect the accuracy of metabolic and endocrine screenings, making it important to follow the NBS guidelines for re-screening and follow-up as appropriate.

#### **Parenteral Nutrition**

Parenteral nutrition (PN) may cause marked elevations in amino acid and acylcarnitine profiles, leading to potential false-positive results. Please collect the specimen before initiating PN whenever possible. If the specimen cannot be obtained prior to starting PN, a follow-up specimen should be collected 48-72 hours after it is discontinued to allow for the return to baseline. Please check the "Yes" box for TPN on the NBS DBS card to account for the potential influence on the screening results.

#### **NPO/ IV Fluids Only**

When an infant is NPO or only receiving IV fluids, newborn screening should continue according to NICU admission newborn screening criteria. While newborn screening can be performed without oral or enteral feeding, it is important to recognize that feeding activates certain metabolic pathways essential for the accurate detection of specific conditions. Without feeding, there is a potential for missed opportunities to identify conditions that rely on metabolic processes triggered by feeding such as phenylketonuria (PKU), maple syrup urine disease (MSUD), and galactosemia. Despite this potential reduction in accuracy for feeding-dependent conditions, other conditions which do not rely on feeding for diagnosis, such as hypothyroidism, cystic fibrosis, sickle cell disease, etc., which are part of the core screening panel, can still be assessed. Adhering to the NBS guidelines ensures the early detection of life-threatening conditions and prevents missed diagnoses, enabling timely intervention and optimal outcomes.

#### **Older Infants/Children**

Screening of infants older than 3 months old may yield in unreliable results, as reference ranges for markers (other than the hemoglobinopathies) are validated only for the newborn period. For infants up to 12 months of age who were not screened as newborns or lack available screening results, a new specimen should be collected and interpreted alongside clinical and physical findings.

## SECTION 6: PREVENTING SUBMISSION OF NEWBORN SCREENING CARDS THAT ARE UNSATISFACTORY FOR TESTING

### 6.1 REQUIREMENTS FOR NEWBORN SCREENING CARD ACCEPTABILITY FOR TESTING

#### **Demographic Data Inspection**

The Georgia Public Health Laboratory reviews the NBS DBS card to ensure patient information, date and time of birth, date and time of collection, submitter, and clinician information are complete. NBS DBS cards that lack this information cannot be reported until the missing information is resolved, or the specimen is re-collected.

#### **Quality Inspection of Newborn Screening Cards**

Prior to testing, dried blood spot specimens are inspected by the Georgia Public Health Laboratory to ensure that each circle has the amount of blood required for the performance of testing. Georgia Public Health Laboratory inspects all NBS DBS cards to verify that the entire circle is filled with blood and the blood has soaked into the filter paper.

#### **Example of a Satisfactory Specimen:**

Circles are filled completely to the outer edge and evenly saturated. The reverse side looks the same. All demographic information is provided.



## 6.2 CATEGORIES OF UNSATISFACTORY RESULTS

An NBS DBS specimen with a suboptimal quantity or quality of blood or missing demographic or clinical data is deemed unsatisfactory. Samples deemed unacceptable for testing are reported as "UNSATISFACTORY – PLEASE RESUBMIT." Unsatisfactory specimens result in the inconvenience and cost of re-collection of a specimen and delays in results, placing the infant at risk for a delayed diagnosis. It is the responsibility of the birthing facility and listed provider to ensure specimens are collected correctly, and the NBS DBS demographic information is correct and complete.



#### Georgia Newborn Screening Program

Newborn Dried Blood Spot (DBS) Collection Satisfactory and Unsatisfactory Specimens

It is important to collect and submit satisfactory newborn dried blood spot (DBS) specimens. Submitting unsatisfactory DBS specimens can result in delays in screening, placing the newborn at risk for delayed diagnosis.



Satisfactory specimen — Circles are filled completely to the outer edge and evenly saturated. The reverse side looks the same.

#### **Unsatisfactory Specimens**



**Layered specimen** — Blood was applied multiple times to the same circle or the circle was filled on both sides of the filter paper.

**Insufficient quantity of blood** — Circles are not completely filled. The reverse side is often poorly saturated as shown.

**Poor saturation** — The reverse side of circles are not completely filled as shown in the examples.

Heel pressed against filter paper — Specimens often have poor saturation on the reverse side as shown.

Blood is chafed/abraded/torn — This can happen when blood is applied using a capillary tube or other device.

Serum rings — Possible causes: anemic infant, excessively squeezing area surrounding puncture site, allowing filter paper to come in contact with alcohol, applying blood to filter paper with a capillary tube.

The Georgia Public Health Laboratory Newborn Screening Unit can be contacted with questions at (404) 327-7950. Additional information is available at: <u>www.dph.ga.gov/NBS</u>.

CODE	REASONS FOR SPECIMENS TO BE DETERMINED TO BE "UNSATISFACTORY – PLEASE RESUBMIT"
1	<b>Oversaturated:</b> Excessive application of blood; applying blood to both sides of the filter paper.
2	<b>Delayed:</b> Received >10 days after the date of collection.
3	<b>Contaminated:</b> Excessive squeezing of the puncture site produces serous fluid; filter paper in contact with alcohol/antiseptic solution, hand lotion or powder, food, or water.
4	<b>Uneven Saturation:</b> The circle is not filled completely with blood and/or blood soaked through the filter paper from front to back.
5	<b>Capillary (Scratched/Abraded):</b> Uneven application of blood from a capillary tube. Capillary tubes have heparin which may lead to diluted or contaminated specimens.
6	<b>Expired Form:</b> Out of date or obsolete form. Always check the expiration date printed on the NBS DBS card.
7	<b>Crumpled:</b> Grossly oversaturated, excessive blood application that results in clumps or retraction of the filter paper (appears as though filter paper was put in water and then dried)
8	<b>Roughed Up:</b> Excessive handling of the specimen card or drying the specimen with heat.
9	<b>No Blood / Grossly QNS:</b> No blood on the card; scant amount of blood applied to the card.
10	Insufficient Information: Data not entered on the form.
11	<b>Blood Reattached to Form:</b> Filter paper with blood is stapled or reattached to the form, unable to verify that the blood specimen belongs to a specific child.
12	<b>ID Mismatch:</b> Mismatch of information on the NBS DBS card.
13	Specimen Damage in Transit: Screen unsuitable for testing.
14	<b>Invalid/Illegible Demographics:</b> Data on the form is not valid (e.g., the date of collection is prior to the date of birth; the submitter's handwriting is not legible).
15	Lab Accident: Lab accident.
16	Incorrect Name and/or Blood: Incorrect name and/or blood.
17	Missing Infant Name: No infant name listed.

CODE	UNSATISFACTORY REASON CONTINUED
18	<b>QNS (Quantity Not Sufficient):</b> The quantity of blood is not sufficient for testing.
19	Other: Other
20	Clots in Blood: Clots visible on blood spots.
21	Improperly Dried: Blood on the flap of the card; heat used on the specimen.
22	<b>Pale Blood:</b> Blood is pale, indicating a low hematocrit, and appears watery, thin, and pink in color.

## 6.3 CORRECTING AN UNSATISFACTORY NEWBORN SCREENING CARD

It is the responsibility of the birthing facility and the listed provider to contact the parents/guardians of an infant from whom the initial specimen was unsatisfactory to coordinate a repeat NBS DBS specimen collection.

Submitters who collected what is determined to be an unsatisfactory specimen will receive written notification from the Georgia Public Health Laboratory advising them of the reason that the initial specimen was unsatisfactory and the need to recollect and submit a specimen using a new NBS DBS card.

Submitters who have failed to include information on the NBS DBS card that is required for testing, will receive written notification and a Request for a Corrected Report form (<u>Appendix O: Newborn Screen Correction Form</u>). Submitters are required to complete, print, sign, and fax the form to the laboratory at **(404) 327-7919** for testing of the submitted specimen to be completed and the results to be finalized and reported.

## SECTION 7: CRITICAL CONGENITAL HEART DISEASE (CCHD) SCREENING

### 7.1 CCHD OVERVIEW

Congenital heart defects (CHDs) are problems with the heart's structure that are present at birth. Congenital heart defects are the most common birth defects and occur in almost 1% of births. There are many types of heart defects, with different degrees of severity based on size, location, and other associated defects. Critical Congenital Heart Disease (CCHD) screening with pulse oximetry is used to detect 12 CCHD conditions and six non-CCHD, secondary conditions.

Note: CCHD screening with pulse oximetry is only one tool for identifying newborns with CCHD. Due to the test's limitations and the characteristics of certain CCHD types, the sensitivity of pulse oximetry screening for

CCHD ranges from 50% to 76%. As a result, it is important to understand that CCHD cannot be ruled out based solely on "passing" pulse oximetry screening. Additionally, even when CCHD is excluded, pulse oximetry may still detect other hypoxemic conditions.

#### **Core Conditions (CCHD)**

- Coarctation of the aorta
- Double outlet right ventricle
- Ebstein's anomaly
- Hypoplastic left heart syndrome
- Interrupted aortic arch
- Pulmonary atresia
- Single ventricle (not otherwise specified)
- Tetralogy of Fallot
- Total anomalous pulmonary venous return
- D-Transposition of the great arteries
- Tricuspid atresia
- Truncus arteriosus
- Other critical cyanotic lesions not otherwise specified

#### Secondary conditions (non-CCHD)

- Hemoglobinopathy
- Hypothermia
- Infection, including sepsis
- Lung disease (congenital or acquired)
- Non-critical congenital heart defect
- Persistent pulmonary hypertension
- Other hypoxemic conditions not otherwise specified

CCHD is life-threatening and requires intervention in infancy. CCHD is not always detected prenatally or upon exam in the nursery. As a result, some infants with CCHD are discharged from the nursery to home, where they quickly decompensate. The Georgia NBS Program requires every newborn to receive a pulse oximetry screen for CCHD after twenty-four (24) hours of life or before discharge, whichever comes first.

Pulse oximetry, or "pulse ox," is a simple, noninvasive, and painless test that measures the percent oxygen saturation of hemoglobin in the blood.

# 7.2 CCHD SCREENING POLICIES AND PROCEDURES

All infants born in Georgia should be screened for CCHD. However, infants who have already received an echocardiogram for any reason may be excluded from screening.

**Personnel:** CCHD screening should be conducted by individuals who have pulse-oximetry testing within their scope of practice, who are trained in the use of pulse oximetry and the CCHD algorithm, and who regularly use pulse oximetry for other purposes.

#### **Timing of Screening:**

- Screening should occur as close to 24 hours of age or as close to discharge as possible.
- If the infant is admitted into a NICU or SCBU, the screening test should occur prior to discharge or once the infant is weaned from supplemental oxygen.

#### **Screening Environment:**

Pulse oximetry screening should take place in a quiet space, away from noises and harsh light.

#### Equipment:

A birthing facility-grade pulse oximeter designed for use in infants.

#### **Screening Algorithm:**

The following algorithm adapted from the American Academy of Pediatrics (AAP) endorsed screening algorithm must be used for CCHD screening. Oster ME, Pinto NM, Pramanik AK, et al; American Academy of Pediatrics, Section on Cardiology and Cardiac Surgery, Section on Hospital Medicine, Committee on Fetus and Newborn. Newborn Screening for Critical Congenital Heart Disease: A New Algorithm and Other Updated Recommendations: Clinical Report. Pediatrics. 2025;155(1): e2024069667.

#### **CCHD Screening Procedure:**

- 1. Perform pulse oximetry screening in a quiet space, away from noises and harsh light (e.g., bilirubin lamps and infrared light).
- 2. Assure that the skin is clean and dry before placing the probe on the infant. Skin color and jaundice do not affect the pulse oximeter reading.
- 3. Swaddle the infant to reduce infant movement and crying.
- 4. The screening should occur in the right hand and on either foot. If using only one pulse oximeter, test one site right after the other.



**RH** Application

Foot Application Site

- 5. Place the probe on the palm or sole of the hand or foot, wrapping the light emitter around the lateral aspect of the hand or foot.
- 6. The photo emitter and light emitter must be directly opposite each other in order to obtain an accurate reading
- 7. Secure the probe to the infant's hand or foot using the adhesive or foam tape recommended by the vendor. Do not hold the probe with your own hand.
- 8. Allow the pulse ox to remain on the infant's hand or foot for at least 30 seconds before attempting to obtain a reading. Ensure that the pulse wave (arterial pulse) is consistent, indicating that perfusion to the site being monitored is without motion artifacts.

- 9. Measure and record baseline oxygen saturation.
- 10. Use the CCHD screening algorithm adapted from AAP to determine the outcome.
  - a. Refer to algorithm.
    - i. "Pass result"
    - ii. "Fail result" = Action needed
- 11. Provide appropriate follow-up as needed once results from pulse oximetry screening are completed.

#### Algorithm for Critical Congenital Heart Disease (CCHD) Screening with Pulse Oximetry:



Adapted from Oster ME, Pinto NM, Pramanik AK, et al; American Academy of Pediatrics, Section on Cardiology and Cardiac Surgery, Section on Hospital Medicine, Committee on Fetus and Newborn. Newborn Screening for Critical Congenital Heart Disease: A New Algorithm and Other Updated Recommendations: Clinical Report. Pediatrics. 2025;155(1): e2024069667

Screening results and any subsequent activity should be recorded in the infant's medical record.

## 7.3 ABNORMAL CCHD RESULTS

The AAP-endorsed guidelines for the referral of infants with abnormal CCHD screening results should be followed. Infants who fail a screen should not be discharged until a follow-up assessment is completed. Although infants may appear well at the time of the failed screen, those with CCHD may rapidly decompensate as the ductus arteriosus closes, so follow-up on the failed screen should happen before an infant is discharged, rather than as a scheduled follow-up.

#### AAP Guidance after a Failed Screen

The first step is to examine the infant to ensure hemodynamic stability and then begin the process of evaluating for hypoxemia. Depending on the infant's status, this could involve evaluating for sepsis or pneumonia. Any signs or symptoms of congenital heart defect should prompt rapid evaluation, including potential urgent transfer to a center with advanced care capabilities.

If the infant is asymptomatic and otherwise well with no obvious cause for hypoxemia, a cardiologist or neonatologist should be consulted, and an echocardiogram should be performed. Infants should not be discharged home until the underlying reason or hypoxemia has been identified or the hypoxemia has resolved.

Each birthing facility should have a system in place with access to the following:

- Cardiac specialist or neonatologist consultation.
- An echocardiogram can be performed.
  - 1. All birthing facilities and birthing centers shall be equipped to conduct a CCHD screening test on newborn babies in accordance with the Georgia Newborn Screening Program Policy and Procedure Manual.
  - 2. When a live birth occurs in any birthing facility, birthing center, or facility that is equipped to conduct a CCHD screening test, the test shall be conducted prior to the infant's discharge in accordance with the Georgia Newborn Screening Policy and Procedure Manual. Infants who have already received an echocardiogram for any reason may be excluded from CCHD screening.

### 7.4 CCHD REPORTING REQUIREMENTS

All birthing facilities must document each infant's pulse oximetry-CCHD screening results in the patient's medical record. Results must also be provided to parents or legal guardians and reported to DPH. There are two methods of reporting to DPH, as indicated below.

- NBS DBS Card Write CCHD results on the NBS DBS card and mail them to Georgia Public Health Laboratory. Use this method if CCHD has been completed at the time of NBS DBS collection. See <u>Section 4.2 Guidance for Completing the Newborn Screening Card</u>.
  - Do not hold the NBS DBS card pending CCHD results. Send NBS DBS card to Georgia Public Health Laboratory as outlined in <u>Section 2: Responsibilities in the Newborn Screening Process</u>.

OR

2. **Delayed Screening Report** (<u>Appendix J: NBS Delayed Screening Report Form</u>) - Method to be used only if CCHD screening was completed after the NBS DBS card was submitted.

- Fax a copy of the delayed screening report form to the Georgia Newborn Screening Program at (404) 657-2773 or email to <u>DPH-NBS@dph.ga.gov</u>. The form can be accessed at <u>www.dph.ga.gov/NBS</u>.
- Place the original form in the medical record.
- Do **not** hold the NBS DBS card pending hearing and/or CCHD screening results.

## 7.5 CCHD IN SPECIAL POPULATIONS

#### NICU/SCBU

A CCHD screening test shall be performed prior to NICU/SCBU discharge or at least 24 hours after the baby has been weaned to room air with no supplemental oxygen, or any respiratory support should have an FiO2 of 21%. If weaning to room air prior to discharge is not possible, then echocardiography is warranted and screening with pulse oximetry is unnecessary.

#### **Prenatal CCHD Diagnosis**

Pulse oximetry is not indicated for newborns diagnosed with congenital heart disease prenatally, as their condition has already been identified and is being actively managed. These infants will receive an ECHO. Additionally, infants who have already received an ECHO for any reason may be excluded from CCHD screening.

#### Home Births or Infants Discharged Prior to CCHD Screening

CCHD screening can be performed in the primary care setting. The delivery facility should notify the infant's pediatric provider about the missed screening so that screening can be coordinated as soon as possible (e.g., first outpatient visit). Pediatric providers that perform CCHD screenings should have a referral plan for infants who need a repeat screening or an ECHO.

## SECTION 8: NEWBORN HEARING SCREENING

## 8.1 NEWBORN HEARING SCREENING OVERVIEW

All infants born in Georgia must have their hearing screened unless parents refuse due to religious objection. See <u>Appendix D: Parent/Guardian Refusal of Newborn Screening</u> and <u>Appendix E: Declaration of Religious</u> <u>Objection to Newborn Screening Form.</u>

A team of professionals, including audiologists, physicians, audiology technicians, and nursing personnel, is needed to establish and maintain the newborn hearing screening program. An audiologist should be involved in training staff and establishing protocols. Birthing facilities and agencies should designate a physician to oversee the medical aspects of the program.

Timely follow-up testing following a failed hearing screening is critical. There are <u>18 Early Hearing Detection</u> and Intervention (EHDI) coordinators located around Georgia who help ensure infants who fail their newborn hearing screening receive timely follow-up. Accurate screening and efficient reporting by the birthing facility are critical in determining the success of these follow-up efforts.

## 8.2 NEWBORN HEARING SCREENING POLICIES AND PROCEDURES

**Personnel:** Hearing screening should only be conducted by individuals who have completed the hearing screening training curriculum directed by an audiologist licensed in Georgia with initial and annual competency documented. See <u>Appendix G: Training and Educational Resources</u>.

#### **Timing of Screening:**

- Infants must be >32 weeks gestational age.
- Infants should be in stable condition, preferably off oxygen and antibiotics for 24 hours.
- At a minimum, infants must be ≥6 hours of age prior to their hearing screening. Infants should have their hearing screened as close to discharge as practical, while also allowing sufficient time for a single repeat screen to be performed.
- If an infant fails their initial hearing screening, **one repeat screening** (final screening) may be completed at least 4 hours after the first screening

#### **Screening Environment:**

Newborn hearing screening may be performed in the nursery, parent's birthing facility room, designated quiet room, or NICU. It is best to select an area that is quiet and free of electrical interference. Infants must be asleep and/or very calm and quiet for hearing screening. In many cases, it is best to leave an infant in the caregiver's arms during the test.

#### **Equipment:**

There are two technologies available for screening of hearing in newborns:

 Automated Auditory Brainstem Response (aABR)\* – aABR measurements reflect the status of the peripheral auditory system, the eighth nerve, and the brainstem auditory pathway. The screening level may not exceed 35dB HL.

\*Infants with a NICU stay >5 days are required to be screened using aABR, as OAEs can miss Auditory Neuropathy Spectrum Disorder (ANSD)

2. Automated Otoacoustic Emissions (aOAE) – OAEs reflect the status of the peripheral auditory system, specifically measuring cochlear (outer hair cell) function.

#### **Equipment Maintenance Requirements:**

- Equipment must be calibrated according to the manufacturer's recommendation (annually) and monitored with monthly checks to ensure proper operation.
- Calibration certificates must be kept on record annually.
- Logs must be maintained to show monthly equipment checks and any equipment issues with dates and explanations.
- Birthing facilities should have alternate plans for newborn hearing screening in the event of equipment malfunction.

#### **Hearing Screening Procedure:**

- 1. Ensure the infant is medically stable, >32 weeks gestation, and  $\geq$ 6 hours old (ideally >12 hours old).
- 2. Assess the infant's status and only attempt the screening if it is asleep and/or very calm. Consider hearing screening immediately after feeding to increase the likelihood of the infant being calm for testing.
- 3. Have a caregiver hold the infant and/or swaddle the infant if able.
- 4. Set the infant up for hearing screening per the manufacturer's instructions.
- 5. Begin the hearing screening.
- 6. Assess for validity of hearing screening:
  - a) Is the infant quiet and/or asleep?
  - b) Are electrodes (if applicable) on well with low impedance?
  - c) Are earphones and/or inserts on the ears?
  - d) Is the room quiet?

-If **yes** to all the above, proceed with testing, as the results should be valid.

-If **no** to any of the above, pause the screening, correct the issue, and then resume screening.

7. Equipment will provide a result of "Pass" or "Fail/Refer"

If the infant fails the hearing screening in one or both ears, one additional screening can be completed prior to discharge. You must wait 4 hours in between screenings, and both ears will need to be tested.

## 8.3 NEWBORN HEARING SCREENING RESULTS

#### Pass Result for both ears (initial and/or final screening):

- 1. Report results to DPH (see <u>Section 8.4 Newborn Hearing Screening Reporting Methods and</u> <u>Requirements</u>) and document results in the infant's medical record.
- 2. Inform parents of results verbally and in writing in their preferred language.
- 3. Inform the Primary Care Provider (PCP) on file of results (e.g., in the discharge summary).

#### Fail/Refer Result for One or Both Ears (initial screening):

- 1. Inform the caregiver/s of the results and indicate whether you will be repeating the screening prior to discharge. If you will not be completing a second screening, skip to the *final screening* instructions below.
- 2. It is recommended that the hearing screen be repeated prior to discharge with at least four hours between screenings, if possible.
  - Only one re-screen is permissible prior to birthing facility discharge (a total of two hearing screenings per infant).
  - Rescreening of both ears is required, even if only one ear failed the initial screening.
- 3. You do not need to report the initial screening results, only the *final screening results*.

#### Fail/Refer Result for One or Both Ears (final screening):

1. Report results to DPH (see Section 8.4 Newborn Hearing Screening Reporting Methods and Requirements) and document results in the infant's medical record.

- 2. Inform parents of results verbally and in writing in their preferred language with follow-up recommendations. Utilize <u>Newborn Hearing Screening Results and Recommendation Form</u>
- Educate caregiver/s on the importance of completing follow-up testing (i.e., unidentified hearing loss can cause speech, language, and reading issues; follow-up testing can be very difficult once the infant is >3 months old, as they may not sleep for the test) via access to DPH's <u>"Have You Heard?"</u> resource.
- 4. Provide caregiver/s with follow-up locations. Best practice: Schedule an appointment prior to discharge.
- 5. Inform the Primary Care Provider (PCP) on file of results (e.g., in the discharge summary).

#### Hearing-Targeted Congenital Cytomegalovirus (cCMV) Testing:

As of October 10, 2024, if an infant does not pass the initial or final inpatient newborn hearing screening, in cases where a second screening is performed, the hospital or birthing center shall conduct cCMV testing before discharge or 21 days of age, whichever occurs earlier.

cCMV testing must be completed via urine or saliva Polymerase Chain Reaction (PCR). Saliva Loop-Mediated Isothermal Amplification (LAMP) is also acceptable. For all patients who fail their final hearing screening, the cCMV test status (e.g. pending results, not completed) must be shared with the primary care physician on record (e.g. on the discharge summary) and provided to the family. The final test result must be included in the patient's medical record. All positive cases of cCMV must be reported to DPH within 7 days (best practice is within 72 hours of result).

DPH's designated follow-up program will provide the healthcare provider on record with education, next steps, and assistance with referral coordination on all positive cases of cCMV reported to DPH prior to 21 days of life.

See the <u>Congenital Cytomegalovirus (cCMV) Policy and Procedure Manual</u> and <u>https://dph.georgia.gov/EHDI/ccmv</u> for more information.

## 8.4 NEWBORN HEARING SCREENING REPORTING METHODS AND REQUIREMENTS

NBS DBS Card is the default reporting method unless the birthing facility formally requests a different reporting method. Some birthing facilities may find electronic birth certificates or secure data file transfer advantageous. See <u>Appendix K: Instructions for Selecting Hearing Screening Reporting Method</u> for more information.

#### **Hearing Screening Reporting Methods:**

All birthing facilities must document all newborn hearing screening results and/or status (e.g., pass, fail, missed, transferred, etc.) in the patient's medical record or in a manual log in the hospital unit, report results to DPH, and provide results to the parents or legal guardians.

There are three methods for reporting hearing screening results to DPH. Each birthing facility must notify DPH of their preferred method of reporting (<u>DPH-NBS@dph.ga.gov</u>). Otherwise, NBS DBS card is the presumed method. See <u>Appendix K: Instructions for Selecting Hearing Screening Reporting Method</u> for more information.

#### 1. Newborn Dried Blood Spot Card (+ Delayed Screening Form):

- Write hearing screening results on the NBS DBS card and mail it to Georgia Public Health Laboratory
- Do **not** hold the NBS DBS card to wait for hearing screening results.

#### OR

#### 2. Electronic Birth Worksheet (+ Delayed Screening Form):

- Submit hearing screening results via Electronic Birth Worksheet (Newborn Screening Section)
- Ensure the birthing facility data clerk has access to and is trained on entering newborn hearing screening results into the Electronic Birth Worksheet.
- Ensure the birthing facility has informed DPH of the reporting method selection, as data will not be received unless DPH is made aware to accept the data via this method. For more information, see <u>Appendix K: Instructions for Selecting Hearing Screening Reporting Method.</u>

#### OR

#### 3. Secure Data File Transfer

- Send a CSV file with all required information.
- Ensure the birthing facility has informed DPH of the reporting method selection, as data will not be received unless DPH is made aware to accept the data via this method. For more information, see <u>Appendix K: Instructions for Selecting Hearing Screening Reporting Method.</u>

+Delayed Screening Report Form (Appendix J: NBS Delayed Screening Report Form) – This method should be used in conjunction with the NBS DBS Card and Electronic Birth Worksheet when the final hearing screening is completed after the NBS DBS card or Electronic Birth Worksheet is submitted.

 Fax a copy of the delayed screening report form to the Georgia Newborn Screening Program at (404) 657-2773 or email it to DPH-NBS@dph.ga.gov. The form can also be accessed at <u>www.dph.ga.gov/NBS</u>.

*Each birthing facility must notify DPH of their preferred method of reporting (<u>DPH-NBS@dph.ga.gov</u>), otherwise NBS DBS card is the presumed method.* 

# 8.5 NEWBORN HEARING SCREENING IN SPECIAL POPULATIONS

Infants >5 days in the NICU: Infants must be tested using aABR technology.

**Infants with Congenital Aural Atresia:** Infants with congenital aural atresia in one or both ears or with visible pinna/ear canal deformity such as anotia, stenosis, or severe malformation should not be screened in either ear but should be referred for diagnostic audiologic evaluation immediately. (This can be completed inpatient if an audiologist is on staff. Otherwise, assist family if scheduling as an outpatient).

## SECTION 9: FOLLOW-UP PROGRAM PROCEDURES

## 9.1 METABOLIC CONDITIONS FOLLOW-UP

#### **Emory University Department of Human Genetics Follow-Up Program:**

The Emory Follow-Up program is a contracted service that consists of a team dedicated to reporting, providing support, and gathering data through the follow-up process for all children with an abnormal newborn screen of the following disorders:

- Organic Acid Disorders
- Fatty Acid Oxidation Disorders
- Amino Acid Disorders
- Lysosomal Storage Disorders
- Endocrine Disorders
- Other Disorders

The follow-up team at Emory is responsible for locating the infant with the abnormal result and contacting the health care provider listed on the newborn screening card to report the abnormality, delivering education and resources about the condition, and providing recommendations on how to proceed.

Abnormal newborn screening results are triaged into three categories:

- **Borderline:** These results and recommendations are reported via fax to the provider listed on the NBS DBS card. A letter is also mailed to the family asking them to contact their healthcare provider about the abnormal newborn screen result.
- **Routine abnormal:** The provider listed on the NBS DBS card is called to report the result and recommendations. These calls are then followed by a fax of the information. Letters are not routinely sent to families.
- **Critical abnormal:** The provider listed on the NBS DBS card is called immediately to report the result and recommendations. These calls are then followed by a fax of the information and a subsequent phone call when action has been delayed. Letters are not routinely sent to families currently.

The faxes will contain the screen results, basic information about the disorder and how to assess the child, and the follow-up recommendation.

#### **Emory Follow-Up Contact Information:**

Phone Number: (404) 778-8560 Physician on call (including genetics, endocrinology, immunology, pulmonology): (404) 778-8566 Website: <u>www.med.emory.edu/departments/human-genetics/patient-care/newborn-screening.html</u>

## 9.2 HEMOGLOBIN CONDITIONS FOLLOW-UP

Augusta University, Children's Healthcare of Atlanta, and The Sickle Cell Foundation:

Sickle Cell Disease (SCD) is the most prevalent genetic disorder identified by NBS in Georgia and includes both homozygous (Hb SS) and compound heterozygous forms of SCD (e.g., sickle Hb C disease, sickle  $\beta^{\circ}$  thalassemia, and sickle  $\beta^{+}$  thalassemia). The screening methodologies used also detect a variety of other clinically significant non-sickle hemoglobinopathies, such as homozygous Hb C, hemoglobin C/  $\beta^{+}$  and  $\beta^{\circ}$  thalassemia, homozygous E, hemoglobin E/  $\beta^{+}$  and  $\beta^{\circ}$  -thalassemia disease and others.

Infants with NBS results indicative of SCD or other clinically significant hemoglobinopathies should have confirmatory testing performed as soon as possible in early infancy so that family education and comprehensive care (including prophylactic penicillin for those with SCD) can be initiated during the first 2-3 months of age before signs and symptoms usually develop. For infants with SCD, timely completion of these actions is crucial in reducing the morbidity and premature death associated with SCD.

In Georgia, responsibility for ensuring timely follow-up is divided between Children's Healthcare of Atlanta (CHOA) for greater Metro-Atlanta counties and the Division of Pediatric Hematology/Oncology at Augusta University (AU) for all other counties located across Georgia (Athens, Albany, Dublin, Valdosta, and Waycross), and public health departments and agencies throughout the state to ensure that all babies identified with abnormal results receive timely diagnosis and treatment. The programs also utilize outreach and some telemedicine clinics to extend the reach of specialty care in more rural areas. AU operates clinics in Athens, Albany, Dublin, Valdosta, and Waycross, and CHOA has monthly SCD outreach clinics in Columbus. The follow-up teams also provide education and counseling to families and serve as a resource for physicians, partners, and families. Cases are referred to the county health departments as needed and the Office of Child Health district programs for child health intervention services.

Newborn screening also identifies healthy heterozygous carriers of sickle cell trait and other hemoglobin variants (e.g., Hb C, D, E) as well as some with thalassemia. The Sickle Cell Foundation of Georgia (SCFGa) and AU Sickle Cell Program provide treatment, counseling, and education to families of infants affected by SCD.

#### Augusta University (AU) Hemoglobin Follow-up Program Contact Information:

- NBS Program Coordinator: (706) 721-6251; On-call MD: (706) 721-5600
- Website: <u>www.augusta.edu/centers/blood-disorders</u>

#### Children's Healthcare of Atlanta (CHOA) Hemoglobin Follow-up Program Contact Information:

- NBS Follow-up Coordinator: (404) 785-1087 or CHOA Hematologist On-call MD: (404) 785-7778
- Website: <u>www.choa.org/medical-services/cancer-and-blood-disorders/blood-disorders</u>

#### The Sickle Cell Foundation of Georgia, Inc (SCFGa):

- SCFGa NBS Coordinator: (404) 755-1641 or 1-800-326-5287 (toll free)
- Website: <u>www.sicklecellga.org</u>

#### Hemoglobin Follow-up Program's Responsibilities

The hemoglobin follow-up programs are contracted services. The follow-up teams at CHOA and AU ensure that abnormal hemoglobin results are reported to the health care provider listed on the NBS DBS card or the current primary care provider. Support is provided to PCPs in educating the family about the results of the newborn screening test and coordination of referral to hematology specialty care for diagnostic testing and appropriate treatment. When necessary, the follow-up teams provide education and counseling directly to

families. Confirmed cases are referred to the Children 1st Program for determination of eligibility for DPH child health intervention services, and results of confirmatory testing are reported through SENDSS.

#### NBS Follow-up Program Coordinators fax the following information to healthcare providers:

- 1. A letter that explains the screening mandate, confirmation process, and contact information.
- 2. Copy of the Georgia Public Health Laboratory NBS report
- 3. Copy of The American College of Medical Genetics, <u>Newborn Screening ACT Sheets and Confirmatory</u> <u>Algorithms</u>
- 4. Confirmatory testing information depending on the follow-up program:
  - 1. AU: Copies of a lab slip for the Titus H.J. Huisman Hemoglobinopathy Laboratory at the Medical College of Georgia at Augusta University.
  - 2. CHOA: A referral is made to the hematology clinic for confirmatory testing at the first visit.

Signs of sickle cell disease can develop shortly after birth, which is why it is important to collect the confirmatory test (hemoglobin electrophoresis and high-performance liquid chromatography) as soon as possible, without delay. Below are resources for the collection of the test:

- The <u>Hemoglobin Reference Laboratory</u> located at Augusta University in Augusta, Georgia, is an international testing and reference center for sickle cell disease, thalassemia, and other hemoglobin disorders. The AU laboratory is one of a few in the country that studies abnormal hemoglobin and is a resource for researchers and providers throughout the country and beyond, it is the preferred testing site for AU confirmatory testing. Testing at AU is free for NBS confirmation of hemoglobinopathy and associated family studies. There may be a fee incurred for other testing; the lab should be contacted directly for additional information.
- The hematopathology laboratory of CHOA or Grady Birthing facility performs capillary hemoglobin electrophoresis five days per week with high-performance liquid chromatography (HPLC) confirmation of all abnormal hemoglobin variants.

#### **Special Circumstances – Transfusions:**

Receipt of a blood transfusion prior to specimen collection confounds the interpretation because the transfused hemoglobin of the blood donor remains in circulation for 120 days. Therefore, it is essential that both the initial NBS and subsequent confirmatory test specimens be collected prior to any blood transfusion. In situations where this is not possible, the prior transfusion history should be clearly indicated by the submitter of the specimen.

#### Abnormal HgB Results for Transfused Infants

Dried blood spot screening results that indicate the presence of sickle hemoglobin and normal hemoglobin in an infant transfused prior to blood collection should be referred as soon as possible to a reference lab for genetic (DNA) testing to exclude sickle cell disease. For confirmatory testing information contact Augusta University (706) 721-6251 and Children's Healthcare of Atlanta (404) 785-1087.

#### Follow-up Recommendations:

Post-transfusion confirmatory testing (HPLC, IEF, or DNA testing) should be completed in consultation with the newborn screening hematology consultant.

#### Healthcare Provider's Responsibilities:

The provider listed on the NBS DBS card is responsible for contacting the family to arrange diagnostic testing and follow-up. If the provider is not following the patient, the NBS follow-up team attempts to identify the current primary care provider (PCP). If no PCP is identified, the NBS follow-up team contacts the family directly to provide the results of the abnormal newborn screen.

#### PCPs are asked to do the following:

- Contact the family to schedule an appointment as soon as possible and share the NBS results and educational literature with them during the initial visit.
  - Notify the NBS Follow-up Coordinator if the family is seeing another healthcare provider.
  - If no provider can be located, provide notification about the abnormal results to the family by phone or by certified mail if unable to reach them by phone.
- Refer all NBS cases to a pediatric hematologist or SCD (Sickle Cell Disease) outreach clinic.
  - If confirmatory testing is performed before the first hematology visit, please fax the results to the NBS Follow-up Coordinator.
- Educate caregivers on the basics of SCD, including its genetic component, the immediate need for penicillin prophylaxis, and the benefits of protein-conjugated pneumococcal immunizations.

The NBS Follow-up Coordinators should make every attempt to contact the patient's PCP office to facilitate penicillin prophylaxis initiation within one month of birth (if warranted) and ensure SCD diagnosis confirmation. The NBS Follow-up Coordinator should notify the NBS Program to engage CHOA or Augusta University for evaluation of the need for penicillin prophylaxis and confirmatory diagnosis.

If the patient doesn't have a PCP or the parents refuse PCP recommendations, the NBS Follow-up Coordinator will contact the families with information about the abnormal test and assist with identifying a PCP and other interventions as needed for diagnosis confirmation.

### 9.3 NEWBORN HEARING SCREENING FOLLOW-UP

DPH has 18 Early Hearing Detection and Intervention (EHDI) district coordinators located around Georgia who can assist families in locating timely follow-up hearing testing.

To locate the EHDI coordinator for your health district, visit the <u>Women, Children, and Nursing Service Locator</u> and filter by the "Early Hearing Detection and Intervention" program.

# 9.4 FOLLOW-UP PROGRAM CONTACT INFORMATION

#### **Emory Follow-Up Contact Information**

The Emory Follow-Up program provides follow-up for infants with an abnormal newborn screen of the following disorders:

- Organic Acid Disorders
- Fatty Acid Oxidation Disorders
- Amino Acid Disorders
- Lysosomal Storage Disorders
- Endocrine Disorders
- Other Disorders

Phone Number: (404) 778-8560

Physician on call (including genetics, endocrinology, immunology, pulmonology): (404) 778-8566 Website: <u>www.med.emory.edu/departments/human-genetics/patient-care/newborn-screening.html</u>

#### Augusta University (AU) Hemoglobin Follow-up Program

The AU follow-up program provides follow-up for infants with NBS results indicative of SCD or other clinically significant hemoglobinopathies in designated locations outside of the greater Metro-Atlanta area.

- NBS Program Coordinator: (706) 721-6251; On-call MD: (706) 721-5600
- Website: <u>www.augusta.edu/centers/blood-disorders</u>

#### Children's Healthcare of Atlanta (CHOA) Hemoglobin Follow-up Program

The CHOA follow-up program provides follow-up for infants with NBS results indicative of SCD or other clinically significant hemoglobinopathies within the Greater Metro-Atlanta area and areas in the northwest part of the state.

- NBS Follow-up Coordinator: (404) 785-1087 or CHOA Hematologist On-call MD: (404) 785-7778
- Website: <u>www.choa.org/medical-services/cancer-and-blood-disorders/blood-disorders</u>

#### The Sickle Cell Foundation of Georgia, Inc (SCFGa): Hemoglobin Traits/Carriers Follow-up

The Sickle Cell Foundation of Georgia, Inc. (SCFGa) is responsible for following up on abnormal hemoglobin results that suggest a carrier or "trait" status (sickle C, D, E, and alpha thalassemia). The SCFGa staff provides testing, counseling, and education for the Georgia Newborn Screening Program. Additionally, SCFGa serves as a specimen collection site for confirmatory testing of clinically significant hemoglobin disorders and family studies.

- SCFGa NBS Coordinator: (404) 755-1641 or 1-800-326-5287 (toll-free)
- Website: <u>www.sicklecellga.org</u>

#### Early Hearing Detection and Intervention (EHDI) District Coordinators:

There are 18 EHDI coordinators located throughout Georgia, 1 per health district. The district EHDI coordinator will assist infants who failed their hearing screening get follow-up testing within 3 months of age.

To locate the EHDI coordinator for your health district, visit

<u>https://sendss.state.ga.us/ords/sendss/!mch.coord\_search</u> and filter by "Early Hearing Detection and Intervention" program.

## SECTION 10: APPENDICES AND REFERENCES 10.1 APPENDICES

### APPENDIX A: GLOSSARY OF TERMS

#### **Newborn Screening Definitions:**

**Abnormal test result**: A test result that is outside the screening limits set forth in the current edition of the Georgia Newborn Screening Program Policy and Procedure Manual.

**Adequate specimen**: A NBS DBS specimen that is properly collected in accordance with the current edition of the Georgia Newborn Screening Program Policy and Procedure Manual.

**Approved laboratory**: A laboratory licensed in Georgia, which has been specifically approved by the Georgia Department of Public Health to conduct laboratory analysis of NBS DBS specimens for the disorders specified in the Georgia Newborn Screening Policy and Procedure Manual.

**Automated auditory brainstem response (aABR)**: A specific test method that measures the brainstem's response to acoustic stimulation of the ear, using equipment that automatically provides a pass/refer outcome.

**Automated Otoacoustic Emissions Testing (aOAE)**: A specific test method that elicits a physiologic response from the outer hair cells in the cochlea, using equipment that automatically provides a pass/refer outcome.

**Birthing center/facility**: Any facility that is licensed by the Georgia Department of Community Health as a birthing center.

**Dried Blood Spot Specimen (DBS)**: This is a blood sample collected on filter paper and air dried before transport to the laboratory for screening.

**Confirmatory test/diagnostic test**: A test to prove or disprove the presence of a specific disease/condition suspected due to NBS results.

**Critical Congenital Heart Disease (CCHD)**: A group of serious heart defects that are present from birth, including coarctation of the aorta (CoA), double-outlet right ventricle, D-transposition of the great arteries, Ebstein's anomaly, hypoplastic left heart syndrome, interrupted aortic arch, pulmonary atresia, single ventricle, total anomalous pulmonary venous connection, tetralogy of Fallot, tricuspid atresia, and truncus arteriosus.

**Gestational age (GA)**: The number of completed weeks in a pregnancy (measured from the first day of the last menstrual cycle until birth).

Low birth weight (LBW): A birth weight of less than 2500 grams.

**Newborn Screening Specimen Card (NBS DBS Card)**: The current version of DPH Form 3491 is used to collect information and blood specimens from a newborn infant.

**Newborn Hearing Screening Test**: The completion of an objective, physiological test or battery of tests administered to determine the infant's hearing status and the need for further diagnostic testing by an audiologist or physician in accordance with the Georgia Newborn Screening Program Policy and Procedure Manual's approved instrumentation, protocols and pass/refer criteria.

**Newborn Screening and Genetics Advisory Committee (NBSAC)**: A multi-disciplinary group of professional and consumer representatives with knowledge and expertise in newborn screening programs appointed by the Commissioner of Public Health.

Parenteral nutrition (PN): Administration of nutrients intravenously.

Preterm/premature: Infant born before 37 completed weeks (259 days) of gestation.

**Recollection**: Collection of another specimen from the same newborn due to an unsatisfactory initial specimen or due to NICU/SBCU admission retesting recommendations.

**Submitter/Submitting Facility**: Any person or entity submitting an NBS DBS card for analysis, typically the birthing facility, birthing facility, midwife, or birthing center.

**Unsatisfactory Specimen (Unsat)**: An NBS DBS specimen that is rejected by the laboratory because the quality of the specimen does not allow for accurate testing or because critical information is missing from the NBS DBS card, which inhibits the laboratory's ability to accurately identify the infant or interpret the test results.

#### Abbreviations and Acronyms:

DPH: Georgia Department of Public Health

cCMV: Congenital Cytomegalovirus

**CF**: Cystic Fibrosis

DBS: Dried Blood Spot

#### GEORGIA PUBLIC HEALTH LABORATORY: Georgia Public Health Laboratory

LBW: Low Birth Weight

NBHS: Newborn Hearing Screening

**NBS**: Newborn Screening

NICU: Neonatal Intensive Care Unit

POC: Point-of-Care

SCBU: Special Care Baby Unit

SCD: Sickle Cell Disease

## APPENDIX B: GEORGIA RULES AND REGULATIONS PERTAINING TO NEWBORN SCREENING

#### **Public Health Regulations**

The Georgia Department of Public Health is authorized by law to enact administrative regulations to protect public health. Thirty-three separate regulations chapters, each devoted to a particular subject, are available.

Each of Georgia's 159 County Boards of Health is also authorized to enact regulations to protect the public health in their jurisdiction, provided those county regulations do not contradict those of the Department. After reviewing the Department's regulations, you may check with your County Board of Health to see if it has elected to enact supplemental regulations on a particular subject.

#### Web Link to Georgia Public Health Code 511-5-5 Testing for Inherited Disorders in the Newborn

# APPENDIX C: NEWBORN SCREENING PANEL AND DISORDER-SPECIFIC INFORMATION

Organic Acid Disorders	<ul> <li><u>Beta Ketothiolase (BKT)</u></li> <li><u>Cobalamin A and B Deficiency (Cbl A,B )</u></li> <li><u>Glutaric Acidemia type I (GA1)</u></li> <li><u>3-OH 3-CH Glutaric Aciduria (HMG)</u></li> <li><u>Isovaleric Acidemia (IVA)</u></li> <li><u>3 Methylcrotonyl-Co A Carboxylase Deficiency (3MCC)</u></li> <li><u>Multiple Carboxylase Deficiency (MCD)</u></li> <li><u>Methylmalonic Acidemia (MMA)</u></li> <li><u>Propionic Acidemia</u></li> </ul>
Fatty Acid Oxidation Disorders	<ul> <li><u>Carnitine Uptake Defect</u></li> <li><u>Long Chain 3 hydroxyl acyl-CoA dehydrogenase Deficiency</u> (<u>LCHADD</u>)</li> <li><u>Medium Chain acyl-CoA dehydrogenase Deficiency</u></li> <li><u>Trifunctional Protein Deficiency (TFP)</u></li> <li><u>Very Long-chain acyl-CoA dehydrogenase</u> <u>Deficiency (VLCADD)</u></li> </ul>

Amino Acid Disorders Lysosomal Storage Disorders	<ul> <li>Argininosuccinic Acidemia</li> <li><u>Citrullinemia</u></li> <li><u>Homocystinuria</u></li> <li><u>Maple Syrup Urine Disease (MSUD)</u></li> <li><u>Phenylketonuria (PKU)</u></li> <li><u>Tyrosinemia</u></li> <li><u>Mucopolysaccharidosis I (MPSI)</u></li> </ul>
Endocrine Disorders	<ul> <li><u>Congenital Adrenal Hyperplasia (CAH)</u></li> <li><u>Congenital Hypothyroidism (CH)</u></li> </ul>
Hemoglobinopathy Disorders	<ul> <li><u>Sickle Cell Anemia</u></li> <li><u>Sickle Beta Thalassemia</u></li> <li><u>Sickle C Disease</u></li> <li><u>Other Hemoglobin Variants</u></li> </ul>
Other Metabolic Disorders	<ul> <li><u>Biotinidase Deficiency</u></li> <li><u>Cystic Fibrosis (CF)</u></li> <li><u>Galactosemia</u></li> <li><u>Severe Combined Immunodeficiency (SCID)</u></li> <li><u>Spinal Muscular Atrophy (SMA)</u></li> <li><u>X-linked Adrenoleukodystrophy (X-ALD)</u></li> <li><u>Krabbe Disease</u></li> </ul>
Critical Congenital Heart Disease (CCHD)	<u>Critical Congenital Heart Disease (CCHD)</u>
Congenital Hearing Loss	<u>Congenital Hearing Loss</u>

## APPENDIX D: PARENT/GUARDIAN REFUSAL OF NEWBORN SCREENING

Every infant born alive in Georgia shall receive newborn screening, unless the infant's parents or legal guardians object in writing on the grounds that such tests and treatment conflict with their religious beliefs.

The following process must be completed when a parent or legal guardian refuses to consent to newborn screening:

- a) Notify appropriate birthing facility staff and infant care provider.
- b) Provide parent with a copy of the NBS brochure, <u>What Every Parent Should Know (DPH form #5506)</u>
- c) Document parent's confirmation that brochure was read, and questions were answered.
- d) Offer parent <u>NBS video</u> to view.
- e) Document parent confirmation of understanding the purpose of performing NBS.
- f) Request the parent complete and sign institution's refusal form or DPH's Declaration of Religious Objection to NBS form (Appendix E: Declaration of Religious Objection to Newborn Screening Form).
- g) The refusal form must be signed by a witness.
- h) Place copy of signed refusal form in infant's medical record
- i) Fax the completed Refusal Form to DPH (404) 657-2773 or email to DPH-NBS@dph.ga.gov
- j) Document parent refusal in the appropriate box on the NBS DBS card and Ship/Mail the NBS DBS card to Georgia Public Health Laboratory.
- k) If parent agrees to newborn hearing and CCHD screening but not blood screening, document hearing and CCHD results on the NBS DBS card (or whichever reporting method facility has selected), document parental refusal of blood screening and ship/mail NBS DBS card to the Georgia Public Health Laboratory.

## APPENDIX E: DECLARATION OF RELIGIOUS OBJECTION TO NEWBORN SCREENING FORM

		D	oclaration		ligious Ohi	action to	
		De	eciaration	i oi kei	igious Obj	ection to	
GEORGIA DEPARTME	NT OF PUBLIC HEALTH		INEW	/born S	screening		
The <b>Georgia D</b> tested for certa screening testin	epartment of Public He in conditions which pose ng includes blood screeni	alth Code a threat of ng, hearing	Rule 511-5-5 ma f severe illness, ph g screening, and s	ndates that al ysical or deve creening for o	ll newborn babies in e elopmental disability, critical congenital hea	Georgia are promptly or death. Newborn art disease (CCHD).	
Babies born ou	itside of a hospital, birthin	ig center, o	or other healthcare	e facility are a	lso required to be sc	reened.	
Parents or lega religious belief	I guardians can decline n s as outlined in Rule 511-	ewborn scr 5-503.	reening on the gro	ound that such	h tests and treatment	t conflict with their	
Instructions: (404) 657-2773 time defined b	Complete and sign the for or email to <u>DPH-NBS@d</u> or the hospital or provider	orm in the ph.ga.gov. policy.	presence of a witr This form shall be	ness. Forward e retained in t	the completed form he child's medical real	to DPH by faxing to cord for the period of	
Child's Name	(Last)	(First)		Child's Date of Birth			
Address						(WIM/DD/TTT)	
City		State	ZIP	one Number			
Parent or Gua	rdian Name (Last)	(First)		elationship to Child	I		
Delivery Loca Hospital / I Other	<b>tion</b> Birthing Center	Deliver	y Hospital / Birt	hing Center	Name		
Select the new	wborn screening test(s)	declined	at birth:			Luset Disease Com	
	imen Screen	Пне	Attention Cter	L	_Critical Congenita	il Heart Disease Scree	
			Attestation Stat	(Darant or	Logal Cuardian's Fi	est and Last Name)	
, affirm that I an	n the parent or legal gua	rdian of t	he child named a	bove.	Legal Guardian's Fi	rst and Last Marrie),	
Initial	I have been informed o designated by the Geor the need for screening Code 511-5-5 and have What Every Parent Shou	f the need rgia Depar to detect been pro uld Know).	I for a blood test tment of Public I critical congenita wided a copy of I	to screen for Health, the ne I heart diseas DPH Form 55	r metabolic or genet eed for newborn hea se as mandated by C 06 ( <i>Georgia Newbor</i>	ic disorders as aring screening, and Georgia Public Health In Screening Program	
Initial	I understand that that t	he Georgi	a Department of	Public Healt	h has determined:		
	<ul> <li>a. that the red threat of se</li> </ul>	quired nev	vborn screening i ss. physical or de	s necessary t velopmental	to identify certain co disability or death:	inditions which pose	
	b. that the red	quired scre	eening tests are s	afe;			
	c. that the ch	ild who do	pes not receive the	e required n	ewborn screening te	ests may have a	
	may need t	reatment	or interventions.	g loss, or a cr	itical congenital nea	nt disease present th	
Initial	I affirm that newborn so screening are not based	creening is d solely or	s contrary to my in grounds of pers	religious beli onal philoso	efs, and that my obj phy or inconveniend	ections to newborn	
Printed Name	1	Signa	iture			Date	
Witness Print	ed Name	Witn	ess Signature			Date	
	Georg	ia Newborn	Screening Program	www.dph.	ga.gov/NBS	Print	
	5.513				Unda	ted 8/2023	

Link to the form: <u>https://dph.georgia.gov/document/document/declaration-religious-objection-nbs-</u> form/download

## APPENDIX F: GEORGIA NEWBORN SCREENING PROGRAM POLICY FOR RETENTION AND USE OF RESIDUAL DRIED BLOOD SPOT (DBS) SPECIMENS

DPH must comply with federal HIPPA requirements to protect the privacy of infants and their families and assure that all specimens are protected from inappropriate use or access.

#### (1) How the newborn screening specimens will be stored:

Upon receipt by the Georgia Public Health Laboratory, DBS cards are either stored refrigerated (2-8°C) or at ambient temperature (18-25°C) until testing is completed. After testing is finished, the DBS cards are stored in a walk-in refrigerator in low gas-permeable, zip-closure bags with desiccant and humidity indicator cards and CDC quality assurance materials (base and elevated DBS cards) as recommended by the Clinical and Laboratory Standards Institute (CLSI) until disposed of.

#### (2) Length of time that specimens will be stored

All DBS cards are retained for 16 weeks after testing is completed to allow for re-analysis if questions arise concerning the test results. Specimens that are determined to be presumptive positive for any of the diseases included in the newborn screening panel are stored for at least one year.

Any parent/guardian who desires to have his/her infant's newborn screening specimen (presumptive positive or confirmed case) destroyed twelve weeks after completion of testing may request such action in writing. Any parent/guardian who desires assurance that his/her infant's specimen has been destroyed after completion of testing may request confirmation of such action in writing.

#### (3) Who will have access to the specimens

Georgia Public Health Laboratory is a secure facility. Access to newborn screening specimens is restricted to Georgia Public Health Laboratory staff involved with specimen receipt, testing, data entry, and laboratory management only.

#### (4) Use of DBS Specimens

Residual DBS specimens and associated demographic information are used to support essential NBS program functions such as NBS program evaluation, quality assurance, result verification, test refinement, and quality improvement initiatives. Retained DBS cards and associated demographic information can be used for the following purposes:

- Laboratory quality control, quality assurance, and improvement
- Verification of equipment calibration
- Evaluation of equipment, reagents, and methods of newborn screening tests for conditions approved for screening by the program.
- Validation of equipment and screening methods
- Internal method development and method validation studies, including the setting of appropriate cutoffs or normal ranges.
- Quality assurance audits and gap analysis.

• For a project of public health importance deemed to be research or non-research for the purpose of public policy or health care operations that has been reviewed and approved by the Georgia Department of Public Health as described below.

De-identified NBS DBS samples may be sent to another laboratory when the reason for sending the sample is:

- Participation in a specimen exchange program designed to improve the quality of testing in newborn screening laboratories; or
- Collaboration with another laboratory in developing or validating a newborn screening method. This use requires a statement from the laboratory requesting the specimens that specifies how the specimens will be used, and written approval from the GPHL Director.

#### (5) Release of Specimens to Another Entity

DBS samples may be transferred to other entities as delineated below:

- An entity that has a contract with the *Public Health Department* to perform additional (i.e., second tier) testing in response to an out-of-range screening result.
- A health care provider at the request of the patient, legal guardian, or legal representative after completing and signing a written request form approved by the Public Health Department. See <u>Appendix M: Authorization for Release of Protected Health Information</u>.
- A named person in a legally executed subpoena following review and approval by the attorney general or his/her designee.
- A person to whom release is mandated by order of a court of competent jurisdiction.
- A researcher with written, informed consent from the patient, legal guardian, or legal representative, if the research project has been reviewed and approved by DPH.

#### (6) Research or Third-Party Requests

As part of its public health responsibility to improve newborn screening and public health, the Georgia Department of Public Health will consider study requests to use DBS samples for projects for which informed consent from the legal guardian, or legal representative has been obtained.

Affirmative responses by the Georgia Department of Public Health to a study request using DBSs will depend on, but are not limited to:

- The availability of staff and staff time within the Georgia Public Health Laboratory; and
- Review by the Georgia Department of Public Health's IRB to determine that the study:
  - Compliance with state and federal confidentiality and human subjects research protection requirements.
  - Public health or medical benefit
  - $\circ$   $\;$  Is appropriate for the purpose and intended outcome of the study.

Prior to submitting a formal project proposal to the Georgia Department of Public Health, an investigator should first contact the Director of the Georgia Public Health Laboratory so the Laboratory Director may better understand the proposed project and advise whether the Laboratory will have sufficient resources to meet the request before the investigator initiates the formal project proposal and IRB process with the Georgia Department of Public Health.

#### (7) Disposal

DBS cards will be autoclaved and then handled as medical waste.

# APPENDIX G: TRAINING AND EDUCATIONAL RESOURCES

#### Newborn Dried Blood Spot (DBS) Specimen Collection:

- Georgia Department of Public Health's Newborn Screening Specimen Collection training video
- <u>Newborn Screening: Sample Collection and Handling procedure</u> instructions courtesy of Revvity

#### **Newborn Screening and Genetics:**

- The <u>Centers for Disease Control and Prevention</u> serve as the national focus for developing and applying disease prevention and control, environmental health, health promotion, and health education activities designed to improve the health of the United States's population.
- <u>American College of Medical Genetics and Genomics Newborn Screening ACT Sheets</u>: provides immediate steps for physicians to take upon receiving a positive screen for an infant in his or her practice.
- <u>American Academy of Pediatrics (Georgia Chapter)</u> works to improve the health and welfare of all infants, children, and adolescents in the State of Georgia.
- <u>Clinical and Laboratory Standards Institute (CLSI)</u> provides resources on specimen collection and newborn screening.
- <u>Save Babies Through Screening Foundation, Inc.</u> is a parent resource on newborn screening, provides information for parents, disease description information regarding screening in other states, a resource library, family stories, and much more.
- Sickle Cell Disease Association of America
- <u>Sickle Cell Disease Clinical Guidelines</u>
- <u>Sickle Cell Information Center</u> provides sickle patient and provider education.
- <u>Sickle Cell Foundation of Georgia</u> provides education to Georgia communities to improve the quality of life for people affected by Sickle Cell Disease.
- <u>Cystic Fibrosis Foundation</u> provides CF education and resources.
- National Organization for Rare Disorders

#### **Hearing Screening:**

- <u>Newborn Hearing Screening Automated Auditory Brainstem Response (AABR)</u> serves as a Georgia-specific training resource created by Georgia-licensed audiologists.
- <u>National Center for Hearing Assessment and Management</u> serves as the National Technical Resource Center for all state-based Early Hearing Detection and Intervention (EHDI) programs in the United States.

#### cCMV Testing:

- DPH cCMV Policy and Procedure Manual
- <u>cCMV Implementation Toolkit for Medical Providers</u>

#### **CCHD Screening:**

- <u>Newborn Screening for Critical Congenital Heart Disease (CCHD</u>) resources courtesy of the American Academy of Pediatrics
- <u>Critical Congenital Heart Disease: Updated Newborn Screening Guidelines for Pediatricians training</u> <u>video</u> courtesy of the American Academy of Pediatrics



## Appendix G-1: Dried Blood Spot Specimen Collection Process Algorithm

#### \*Refer to DPH Policy & Procedure Manual Algorithm for CCHD Measurements The Georgia Department of Public Health Code Rule 511-5-5-03 mandates that all newborns have a blood screening, hearing screening, and critical congenital measurements possible if less than 24 hours of age.\* with pulse oximetry after 24 hours of Disease (CCHD) Screening Perform the initial CCHD screening Repeat pulse Report final CCHD result to the **Critical Congenital Heart** Newborn Screening Program age or as close to discharge as in 1 hour. oximetry heart disease (CCHD) screening to identify certain conditions which pose a threat of severe illness, physical or developmental disability, or death. either the right hand Result Result result is <u><90%</u> in Do not repeat if acceccment or foot. Refer ē Newborn Screening (NBS) Guidance for the Well-Baby Nursery Б ECHO; Refer to Repeat CCHD Screening Georgia Newborn Screening Program After 24 Specialist hours of age X \$ \*Must wait 4 hours between screens. Report all final hearing results to the Newborn Screening Program hearing screening prior to discharge. If time permits, perform a repeat Perform the initial hearing screening and all cCMV(+) results Hearing Screening prior to discharge. Result Result e • prior to 21 days of life or Screen infant for cCMV whichever comes first before discharge, Repeat Hearing Discharge Prior to Screening <u></u> feeding, or prior to hospital discharge specimen at 24 to 48 hours after first for newborns dischared before 24 Collect the NBS dried blood spot Dried Blood Spot (DBS) www.dph.ga.gov/EHDI/cCMV for Visit www.dph.ga.gov/NBS or Screening hours of age.

after first

hours

feeding

24 to 48

### Appendix G-2: Newborn Screening Guidance for the Well-Baby Nursery Algorithm



DPH 1/2025

more information.

#### \*Refer to DPH Policy & Procedure Manual Algorithm for CCHD Measurements The Georgia Department of Public Health Code Rule 511-5-5.03 mandates that all newborns have a blood screening, hearing screening, and critical congenital measurements discharge or once the baby is weaned Report final result via DBS card or Perform the initial CCHD screening Repeat pulse Delayed Screening Report form Disease (CCHD) Screening **Critical Congenital Heart** from supplemental oxygen.\* with pulse oximetry prior to in 1 hour. oximetry heart disease (CCHD) screening to identify certain conditions which pose a threat of severe illness, physical or developmental disability, or death. either the right hand esult Result or foot. Refer for result is <90% in Do not repeat if Veonatal Intensive Care Unit (NICU) or Special Care Baby Unit (SCBU) as ses sment. ā Newborn Screening (NBS) Guidance for Infants Admitted into a ECHO; Refer to Repeat CCHD Initial CCHD Specialist Screening Georgia Newborn Screening Program Screening \*Must wait 4 hours between screens. Report all final hearing results to the Newborn Screening Program hearing screening prior to discharge. If time permits, perform a repeat Perform the initial hearing screening and all cCMV(+) results Hearing Screening prior to discharge. Result E. À prior to 21 days of life or Screen infant for cCMV whichever comes first before discharge, Repeat Hearing Screening Discharge **Priorto** specimen upon admission, regardless Collect second NBS dried blood spot discharge, whichever comes first for gestational age or <2,000 grams at specimen between 48-72 hours of life, on infants initially tested <24 Collect third NBS dried blood spot Collect first NBS dried blood spot hours of age at the first screen. specimen at 28 days of life, or treatments are started, except www.dph.ga.gov/EHDI/cCMV for Dried Blood Spot (DBS) of age and before any other infants who were <34 weeks Visit www.dph.ga.gov/NBS or Screening respiratory. more information. birth. Collect Second Collect Third Collect First Specimen Specimen Specimen DPH 1/2025

## Appendix G-3: Newborn Screening Guidance for NICU or Special Care Baby Unit Algorithm

# APPENDIX H: E-REPORTS WEB PORTAL REGISTRATION FORM

	-			Print			
DPF	Newb	born	Screen	ing eReports Web Portal			
GEORGIA DEWATMENT OF PUBLIC HEAD	Tm.	Llo	censea Pro	vlaer Registration Form			
Instructions: Complete	form and fax to (40	4) 321-	2265 or ema	il to <u>dph-nbs@dph.ga.gov</u> . Contact the			
Georgia Department o	of Public Health Newb	oorn Scr	eening Prog	ram with questions at (404) 327-7950.			
Only licen are permitte	ised physicians, p	sician a se num	ssistants, ar bers will be	nd registered professional nurses verified with the State of Georgia.			
Name: (Last)	(First)			Professional License Number:			
Address:				Professional License Type:			
		-		Physician Physician Assistant			
City:	State:	ZIP:		Registered Professional Nurse			
Fax Number:			Phone Nur	nber:			
Email:			Email addres	r will be used to potify user about account approval			
			stat	s will be used to notify user about account approval us, login credentials and to reset password.			
Name of Facility / Prac	tice:			Facility Type:			
				Primary Care			
				Other (specify):			
	Newborn Scr	eening	eReports P	rivacy Statement			
This system allows perso information about indivi- protections under federa	ns authorized by the G duals for reporting and al and state law. The He	eorgia D treatme alth Insu	epartment of nt purposes. 1 rance Portabi	Public Health (DPH) to access protected health This information is entitled to significant privacy lity and Accountability Act of 1996 (HIPAA) permits			
a covered entity to use a	nd disclose protected h	nealth inf	formation with	nout written authorization, if the use or disclosure is			
administrative, technical,	, and physical safeguard	is to pro	tect the priva	cy of protected health information. The disclosure			
of this information to un	authorized persons or f	for unaut	thorized purp	oses is prohibited without the written authorization			
disclosure of this informa	ation may result in signi	ificant cr	iminal or civil	penalties. Failure to properly log out of eReports			
can result in an unauthor	rized disclosure. All acti	ons on t	his website ca	n be monitored and audited. Any unauthorized use			
promptly. Approved use	rs are required to secur	e their el	Reports passv	vord to prevent unauthorized access to the system			
using their password.							
As an authorized user of	eReports you agree to	access t	he database o	nly for reporting and treatment purposes related to			
your patient, and you act this information. As an a	knowledge that you hav uthorized user of eRepo	ve receiv	ed permission agree to reas	n from the infant patient's legal guardian to view onably safeguard protected health information			
from any use or disclosu	re that is in violation of	state or	federal law.				
By signing the form, yo	ou are agreeing to the	eRepor	ts privacy sta	tement above.			
Provider Signature:	ENKX						
Date:							
F	ax completed form to	o (404)	321-2265 o	r email to <u>dph-nbs@dph.ga.gov</u>			
FORM No. NRS-512	Georgia Newborn	Screenin	g Program   <u>v</u>	ww.dph.ga.gov/NBS-Providers			
				opulated T0/2024			

Link to the form: https://dph.georgia.gov/document/document/registration-form/download

# APPENDIX I: AUTHORIZATION FOR RELEASE OF NEWBORN SCREENING REPORT FORM

or en	nail to dph-nbs@dph.g	a.gov. Proof	of identity r	nust be provi	ded (e.g., driver's license).			
Child's N	ame: (Last)	(First)			Child's Date of Birth:	Gender: All Male		
Address:								
City:		State:	Zip:		Birth Facility Name:			
Mother's	Name at Delivery: (Last)	(Maiden)	(First	)	Mother's Date of Birth:			
	AUT	HORIZATION F	OR RELEASE	OF NEWBORN	SCREENING REPORT			
1. l c r	hereby voluntarily authoriz of Public Health (DPH) to di nedical information to:	the Georgia D sclose the reque	epartment ested	Name of Pers Phone: Fax:	on/Facility:			
2. The purpose for this disclosure is for:					patient care scord irement			
3. 1	The information to be disclo	osed includes:		Newborn Screening Report     Follow-up Notes     Other (specify):				
4. 1 a a	This authorization shall become and shall remain in effect un authorization end date or for of signature if no date is en	ome effective im ntil the specified or one year from tered:	the date	Authorization	End Date: (MM/DD/YYYY)			
nitial:	I understand that I may that revocation will not received.	y revoke this aut affect any actio	horization in n taken in re	writing at any t liance on this a	time prior to the release of info uthorization before the written	rmation from DPH, an revocation was		
nitial:	I understand that my e authorization.	ligibility for ben	efits, treatme	ent, or payment	is not conditioned upon the p	rovision of this		
nitial:	I understand that infor longer protected by the	mation disclose e Health Insuran	d by this auth ce Portability	orization may l	be subject to redisclosure by the bility Act (HIPAA).	ne recipient and no		
Patient's	Printed Name:			Patient's Signature:				
Date Sigr	med: (MM/	DD/YYYY)		1				
Authorize	ed Guardian or Represent	ative Printed N	ame:	Authorized (	Suardian or Representative S	ignature:		
Date Sign	ed: (MM/	DD/YYYY)	Relationshi	n to Child:				

Link to the form: https://dph.georgia.gov/media/77981/download

## APPENDIX J: NBS DELAYED SCREENING REPORT FORM

<b>DPH</b>	Newbo	orn Scree	ening (NBS)
GEORGIA DEPARTMENT OF PUBLIC HEALTH	Delayed S	creenin	g Report Form
Instructions: Complete the form to repo	ort hearing and/or critica	l congenital he	art disease (CCHD) screening result(s)
that were not documented on the NDS t	the Code Dedas 511 5 5	OF and 511 F	
by Georgia Department of Public Heal	ith Code Rules 511-5-5	05 and 511-5	-506. Forward the completed form to
the Georgia Newborn Screening Program	n by faxing to (404) 657-	2773 or email	to DPH-NBS@dph.ga.gov.
		P	lace Hospital Label Here
Form/Kit Number (located on NBS card	i)	If the child	's hospital label is not available, please
Child's Mother's Name (First and Last N	Jame at Delivery)	complete t	he Child's Information section. Skip the
child 5 Mother 5 Manie (115t and East 1	anie at Delivery)	Child's Info	ormation if a hospital label is available.
		J	
	CHILD'S INFOR	MATION	
Child's Last Name	Child's First Name		Child's Date of Birth
			(MM/DD/YYYY)
Sex:	Child's Medical Recor	d #	
Male Female			
	SUBMITTER INFO	RMATION	
Submitting Facility Name		Was the infa	ant screened in NICU?
		Yes	No Not Applicable
Was the infant transferred to your	If the child was transf	erred to your	facility, enter the transfer facility's
facility from another facility?	name:		·····,, ·····, ·····, ·
No Yes			
	HEARING SCREENIN	NG RESULTS	
Hearing Screening Date	Left Ear Result:	Right Ear Re	sult: Hearing Screening Method:
(MIM/DD/YYYY)	Pass	Pass	ABR
	Fail	Fail	aOAE
			ABR and aOAE
CRITICAL CONG	ENITAL HEART DISEAS	E (CCHD) SCR	EENING RESULTS
Initial CCHD Screening Date	Right Hand (%)	Foot (%)	Initial CCHD Result
(MM/DD/YYYY)	Pulse Ox Saturation	Pulse Ox Satur	ation (right hand - right foot)
			Pass
			Fail
			Rescreen
Repeat CCHD Screening Date	Right Hand (%)	Foot (%)	Repeat CCHD Result
If rescreen is required, repeat only once, 1-	Pulse Ox Saturation	Pulse Ox Satur	ation (right hand - right foot)
hour after the initial screening.			Pass
(MM/DD/YYYY)			Fail
			Rescreen
ECHO RESULTS (IE APPLICABLE)			
Did the child have an ECHO?	ECHO Date		ECHO Result:
Yes No	(MI		Normal ECHO
		.,,,	Abnormal ECHO
PEEEPRAL INFORMATION (IF FAILED			
Name of Physician or Hospital Peferre	ectro). ed to and Contact Infor	mation:	
Name of Physician of Pospital Refere	ed to and contact mor	mation.	
	Date Reported	to DPH:	Print
Georgia Nev FORM No. NBS-514	wborn Screening Program	m   <u>www.dp</u>	h.ga.gov/NBS Updated 9/2023

Link to the form: https://dph.georgia.gov/media/78476/download

## APPENDIX K: INSTRUCTIONS FOR SELECTING HEARING SCREENING REPORTING METHOD

\*The Newborn Screening Dried Blood Spot Card is the default reporting method unless birthing facility formally requests a different reporting method. Some birthing facilities may find electronic birth certificate or secure data file transfer to be advantageous. See information below to determine what is best for your facility:

	NBS Dried Blood Spot (NBS DBS) Card*	Electronic Birth Certificate +	Secure Data File Transfer
	+	Delayed Screening Form	
	Delayed Screening Form		
Advantages	Utilizes a reliable transit method, requiring minimal extra steps	<ul> <li>Utilizes a reliable transit method, requiring minimal extra steps</li> <li>Requires fewer delayed screening forms, as the Electronic Birth Worksheet is submitted later (day 3-5) than the NBS DBS card</li> </ul>	<ul> <li>Less data entry with fewer errors</li> <li>No need for delayed screening forms</li> </ul>
Disadvantages	<ul> <li>Any infant who has their final hearing screening after the NBS DBS card has been mailed to the lab will require a delayed screening form to be filled out and faxed to DPH; time-intensive; high risk of underreporting</li> </ul>	<ul> <li>Risk of inaccurate information if data clerk is not properly trained</li> <li>Delayed screening form will still be required for babies who are screened <i>after</i> the Electronic Birth Worksheet has been submitted</li> </ul>	<ul> <li>Requires birthing facility and DPH IT involvement to set up a transfer</li> <li>Requires the birthing facility to submit a cleaned report on a weekly basis</li> </ul>

If your facility would like to request hearing screening reporting method be changed from an NBS DBS Card to an Electronic Birth Certificate or Secure Data File Transfer, follow the instructions below:

## Instructions for Selecting Electronic Birth Worksheet as Primary Reporting Method (Complete each step before moving on to the next):

- 1. The birthing facility must train the Data Clerk/s who submit the Electronic Birth Worksheets.
  - Review the current birth worksheet section "Newborn Screening" to ensure understanding of each hearing-related question
  - Ensure they know where to locate the hearing screening results in the Electronic Medical Record

- Ensure they have access to the Newborn Hearing Screening Log in both the well-baby and NICU unit/s as a back-up to locate hearing screening results
- 2. Email DPH at DPH-NBS@dph.ga.gov and request a change from the NBS DBS Card to the *Electronic Birth Worksheet reporting method*.
- 3. Wait for a response indicating the effective start date (typically the first of the following month).
- 4. Birthing facilities should educate their staff on the change in reporting method and leave the NBS DBS card hearing screening results blank.

Instructions for Selecting Secure Data File Transfer as Reporting Method:

- 1. Email DPH-NBS@dph.ga.gov and request a change from the NBS DBS Card to the Secure Data File Transfer reporting method.
- 2. DPH will respond with the next steps (i.e., set up a meeting to share CSV file template and discuss the next steps)

Birthing facilities must document all newborn hearing screening results and/or status (i.e., pass, fail, missed, transferred, etc.) in the patient's medical record, report results to DPH (methods listed above) and provide results to the parents or legal guardians.

## APPENDIX L: FORM TO ORDER NEWBORN SCREEN COLLECTION FORMS (GEORGIA PUBLIC HEALTH LABORATORY) SPECIMEN COLLECTION OUTFIT ORDER FORM

FRM-CA	20 (version 1.0)	GEO	RGIA	PUBLIC H	EALTH	LABOR	ATOR	Y			
		SPECIM	EN C	OLLECTIO	N OUT	FIT ORD	ER FC	DRM			
		Decatur Lab Custo	mer S	Service Phon	e: 404-3	327-7928	Fax:40	04-327-6	862		
INST	TRUCTIONS: Please	e fill out this form completely and p	print le	egibly.							
For the quantity, write the total number of items needed. For example, if you need 100 gold top tubes, enter the quantity as 100 next to the item number 0590.											
<ul> <li>Fax the completed order form to 404-327-6862. Not sure about what to order? We can help with that, just give us a call Decatur Lab Customer Service (404) 327-7928.</li> </ul>											
•	Orders are process available, contact	sed daily in the order they are rece us for scheduling.	ived.	Please allow u	p to 5 d	ays to rece	eive you	ur order.	A pick-up c	ption is	
•	For supplies relate	d to outbreaks, contact your local	epider	niologist or ca	ll the De	ecatur Lab	Custon	ner Servic	e (404) 32	7-7928.	
•	Please remember, submitted to the (	, the supplies provided by the Geo GPHL.	rgia P	ublic Health L	aborato	ry (GPHL)	should	only be u	used for sp	ecimens	
		SUBMITTE	ER INF	ORMATION	(Requir	ed)					
Compar	ny Name		Cont	tact Name				Email Ac	idress		
			Phor	ne Number							
Street A	ddress (NO PO Bo	xes)		Suite/Floor/	Unit	City			State	Zip	
	Co	llection Tubes				Shi	pping S	Supplies			
ITEM	QUANTITY	DESCRIPTION		ITEM	QUAN	ТІТҮ	DESC	RIPTION			
0590	EA	Gold Serum Separator Tubes (SS	T)	0800		EA	Bioha	iohazard Bag w/ Tyvek envelope			
0700	EA	Conical Tube (50mL) for TB		0803		EA	Absorbent Sheet				
0705	EA	Pearl Top Tube (HIV Viral Load) Cryogenic (Pour Off) Tube (HIV V	iral	0805		EA FA	Clear Biohazard Bag Fiberboard Can with Lid				
0/10	20	Load)		0001		24					
0502	EA	HCV Viral Load (Includes Gold To SST & Pour Off Tube)	p	UPS01		EA	UPS Shipping Envelopes				
QFT-1	EA	QFT Tubes		CATB-B		EA	Category B Shipper Only- Limit 5			Limit 5	
0575	EA	Viral Transport Media Kit (VTM) Swab	w	CATB-C		EA	Categ	ory B Shij	oper with (	Cooler- Limit 2	
0505	EA	Viral Transport Media Kit (VTM) NP Swab	w								
0595	EA	Aptima Multitest Kit (STM)							_		
17534	Parasitology	and Bacteriology Supplies		17514	OUIAN	NEW	SORN S	CREENIN	G		
0555	EA	Stool Culture (Para-Pak C&S Oran Top)	nge	3491	QUAN	EA	Newb	orn Scree	en Collectio	on Forms (PKU)	
0545	EA	Para-Pak <sup>®</sup> CLEAN *PREFERRED fo Norovirus PCR	or	3603		EA	Mailir	ng Envelo	pes for Ne	wborn Screen	
0605	EA	Capillary Blood Tube EDTA Purple Top	e								
GEOR	GIA PUBLIC F	HEALTH USE ONLY		FILLED B	Y						
				NO. of BO	XES SI	HPPED					
DATE	RECEIVED			DATE SH	PPED						
The GPHI	L Submission Forms	are also available on the Department o	f Public	c Health Websi	te: http://	dph.georgia	Lgov/lab	v.	Revi	sed 07/14/2023	

Link to the form: <u>https://dph.georgia.gov/document/publication/specimen-collection-outfit-order-form-</u>decatur/download

# APPENDIX M: AUTHORIZATION FOR RELEASE OF PROTECTED HEALTH INFORMATION

Georgia Department of Public Health AUTHORIZATION FOR RELEASE OF PROTECTED HEALTH	ADDRESS   CITY/STATE/ ZIP
1. I hereby voluntarily authorize	to disclose the medica
information indicated below to	
2. The purpose for this disclosure is for	
3. The information to be disclosed is:	
Entire Medical Record Only medical information from t Other (specify)	he periodto
4. This authorization shall become effectiv	e immediately and shall remain in effect until (dal
I understand that I may revoke this authoriz DPH, and that revocation will not affect any	re if no date is entered. ation in writing at any time prior to the release of information from action taken in reliance on this authorization before the written
I understand that I may revoke this authoriz DPH, and that revocation will not affect any revocation was received. I understand that my eligibility for benefits, f authorization.	re if no date is entered. ration in writing at any time prior to the release of information from action taken in reliance on this authorization before the written treatment or payment is not conditioned upon my provision of this
I understand that I may revoke this authoriz DPH, and that revocation will not affect any revocation was received. I understand that my eligibility for benefits, f authorization. I understand that information disclosed by t and no longer protected by the Health Insur	re if no date is entered. ration in writing at any time prior to the release of information from action taken in reliance on this authorization before the written treatment or payment is not conditioned upon my provision of this his authorization may be subject to re-disclosure by the recipient rance Portability and Accountability Act.
I understand that I may revoke this authoriz DPH, and that revocation will not affect any revocation was received. I understand that my eligibility for benefits, i authorization. I understand that information disclosed by t and no longer protected by the Health Insur Print Patient's Name	re if no date is entered. ration in writing at any time prior to the release of information from action taken in reliance on this authorization before the written treatment or payment is not conditioned upon my provision of this his authorization may be subject to re-disclosure by the recipient rance Portability and Accountability Act. Patient's Signature
I understand that I may revoke this authoriz DPH, and that revocation will not affect any revocation was received. I understand that my eligibility for benefits, i authorization. I understand that information disclosed by t and no longer protected by the Health Insur Print Patient's Name	re if no date is entered. tation in writing at any time prior to the release of information from action taken in reliance on this authorization before the written treatment or payment is not conditioned upon my provision of this his authorization may be subject to re-disclosure by the recipient rance Portability and Accountability Act. Patient's Signature Authorized Representative's Signature (if applicable)
I understand that I may revoke this authoriz         DPH, and that revocation will not affect any         revocation was received.         I understand that my eligibility for benefits, f         authorization.         I understand that information disclosed by t         and no longer protected by the Health Insur         Print Patient's Name         Print Authorized Representative's Name (if applicable         Date	re if no date is entered. tation in writing at any time prior to the release of information from action taken in reliance on this authorization before the written treatment or payment is not conditioned upon my provision of this his authorization may be subject to re-disclosure by the recipient rance Portability and Accountability Act. Patient's Signature e) Authorized Representative's Signature (if applicable)
I understand that I may revoke this authoriz         DPH, and that revocation will not affect any         revocation was received.         I understand that my eligibility for benefits, f         authorization.         I understand that information disclosed by t         and no longer protected by the Health Insur         Print Patient's Name         Print Authorized Representative's Name (if applicable         Date         *Psychotherapy notes means notes recorded b         or analyzing the contents of conversation during session and that are separated from the rest of	re if no date is entered. tation in writing at any time prior to the release of information from action taken in reliance on this authorization before the written treatment or payment is not conditioned upon my provision of this his authorization may be subject to re-disclosure by the recipient rance Portability and Accountability Act. Patient's Signature e) Authorized Representative's Signature (if applicable)  y a health care provider who is a mental health professional documen ing a private counseling session or a group, joint, or family counse the individual's medical record. 45 C.F.R. 164.501.

Link to the form:

https://dph.georgia.gov/sites/dph.georgia.gov/files/WicPM/forms/ReleaseOfInformationForm\_Blank.pdf

## APPENDIX N: NEWBORN HEARING SCREENING RESULTS AND RECOMMENDATIONS FORM



### Newborn Hearing Screening Results and Recommendations Form

**Instructions for Staff:** Complete this form and provide a copy to the caregiver/s. Newborn hearing screening results and recommendations are required to be provided to caregiver/s per <u>Rule 511-5-5-.06</u>; <u>Hearing Screening</u>. Note: If you are completing an outpatient hearing re-screen, report results to DPH by faxing this form to (404) 657-2773 or email to <u>DPH-NBS@dph.ga.gov</u>.

#### Place Hospital Label Here

If the child's hospital label is not available, please complete the Infant Demographics section. **Skip** Infant Demographics if a hospital label is attached.

Kaan thi	Congratulations on t	he birth of your baby	/! /:				
Keep this	CHILD'S IN	FORMATION	tatrician appointin	ient.			
Child's Name (First and L	ast):	Child	Child's Date of Birth:				
Data of Torts	HEAKING SCR		Name of Severage				
Date of Test:	□ Inpatient □ Outpatient	inam	e of Screener:				
Type of Test [Select One]	□ OAE + AABR	Nam	Name of Facility:				
	SCREENING RES	ULTS [Select One]					
<ul> <li>Your baby PASSED the r</li> <li>Your baby FAILED the he</li> <li>A failed hearing screening becomes more difficult the of age).</li> <li>If your baby failed their fin Cytomegalovirus (cCMV).</li> <li>Was a Congenital Cytom</li> <li>If yes, what specimen type</li> <li>If known, what are cCMV</li> <li>No further testing screenings as child</li> </ul>	ewborn hearing screening for bor earing screening in the Left   result means your baby needs mo e older the baby becomes and sho al hearing screening before leaving fee <u>https://dph.georgia.gov/EHDI/c</u> egalovirus (cCMV) specimen co be was collected? Saliva <u>rest results? Negative</u> FOLLOW-UP RECOMM is needed (baby passed for both of leaves Seek additional bearing ter	th ears. Right   Both ears ore testing to determi build be completed as g the hospital, they sho comv for more informa llected? Yes Urine Other: Positive Inconc ENDATION [Select C ears). Follow-up with g sting if concerns of be	(CIRCLE ONE) ne if they have a h soon as possible ( build receive a test ; tion. No (CIRCLE (	nearing loss. This test (ideally before 1 month for Congenital ONE) CLE ONE) inown (CIRCLE ONE) utine hearing			
delay arise.	ages. Seek additional hearing te	sting if concerns of ne	aring loss and/or	speecn-language			
Further testing is needed	:						
<ul> <li>A hearing <u>re-scree</u></li> <li>A <u>diagnostic</u> Audit</li> </ul>	<u>n</u> should be scheduled as soon as fory Brainstem Response should b	possible. (Baby failed e completed as soon	one or both ears as possible (Baby	or could not betested) failed inpatient			
Date/Time (if sch	eduled):	lactors)		$\mathbf{O}$			
Location (if school	ulod):						
□ cCMV testing nee	ds to be ordered and conducted p	prior to 21 days of life.	Scan QR to find a follow-up provider at				
			Audiology				

#### Link to the form:

https://dph.georgia.gov/document/document/newborn-hearing-screening-results/download

# APPENDIX O: NEWBORN SCREEN CORRECTION FORM

Newb	orn Scre	een	L					
Corre	ection ro							
	su	Dmit	ter Information	1 (C	completed by	GP	HL)	
Submitter #	Subm	itter:						
Phone#	Addre	55						
Contact Name					Date Faxed			
Submitter Error					GPHL Error			
	Re	port	ed Information	ı (C	ompleted by (	3 Pł	łL)	
		_						
Infant Last Name			Infant First Name				Medical Record #	
GPHL Form #			GPHL Accession #					
Date of Birth			Time of Birth				Birth Weight	
Date of Collection			Time of Collection			Collection Weight		
Correc	ctions (For f Sample qua	fields	s with no chang	ges be	; leave blank resolved with	or : for	strike out clearly). m updates.	
Infant Last Name					Infant First Name	e		
Medical Record #					I			
Date of Birth				Time of Birth				
Date of Collection				Time of Collection				
Birth Weight				Collection Weight				
Please submit one bal	by per form. Submitted a	Supp bove repo	orting documenta is correct. I u ort for this infa	nd nt.	n is no longer red erstand that G Unsigned for	àPH ms	ed if the form is signed. IL will use this information t will not be accepted.	
generate a								

## APPENDIX P: NEWBORN SCREENING PANEL HISTORY

	PUBLIC REALT	H		
Cat	tegory	Core Condition	Abbreviation	Added to GA Panel
		3-Hydroxy-3-Methyglutaric Aciduria	HMG	2007
	S	3-Methylcrotonyl-CoA Carboxylase Deficiency	3-MCC	2007
	itio	ß-Ketothiolase Deficiency	BKT	2007
	puo	Glutaric Acidemia Type I	GA-I	2007
	id C	Holocarboxylase Synthase Deficiency	MCD	2007
	cAc	Isovaleric Acidemia	IVA	2007
	gani	Methylmalonic Acidemia (Cobalamin disorders)	Cbl A,B	2007
	ő	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	MUT	2007
		Propionic Acidemia	PROP	2007
		Carnitine Uptake Defect/Carnitine Transport Defect	CUD	2007
P	5 2	Long-chain L-3 Hydroxyacyl-CoA Dehydrogenase Deficiency	LCHAD	2007
Ac	atio	Medium-chain Acyl-CoA Dehydrogenase Deficiency	MCAD	2003
đ	Diso	Trifunctional Protein Deficiency	TEP	2007
	0 -	Very Long-chain Acyl-CoA Debydrogenase Deficiency	VICAD	2007
		Argininosuccinic Aciduria		2007
_		Citrullinemia Type I	CIT	2007
ino Acid sorders		Classic Phenylketonuria	DKII	1068
		Homocyctinuria	HCV	1070
	And A Strain Contraction of the Disease		MSUD	1970
Tyrosine		Tyrosinemia, Tyros I	TYPI	1070
-		Concentral advectation		1970
End	orders	Congenital adrenal hyperplasia	CAR	1990
015	orders	Primary Congenital Hypothyroidism		1978
	S	S, peta-Indiassemia	HD S/ISTN	1998
	orde	S,C Disease	HDS/C	1998
noglobin Diso		S,S Disease (Sickle Cell Anemia)	Hb SS	voluntary 1998 universal
	Ŧ	Other Hemoglobin Variants	Var Hb	1998
	~	Mucopolysaccharidosis Type I	MPST	2019
	le l	Mucopolysaccharidosis Type II	MPSII	20251
	Diso	Glycogen Storage Disease Type II (Pompe)	POMPE	2025
	Lyso Storage	Krabbe Disease	KD	2021 Pilot 2025 <sup>1</sup>
ŀ		Biotinidase Deficiency	BIOT	2003
۲		Classic Galactosemia	GAIT	1978
- de		Custic Fibrosis	CE	2007
Disc	5	Guanidinoacetate Methyltransferase Deficiency	GAMT	20251
her	Othe	Severe Combined Immunodeficiencies	SCID	2007
õ	-	Spinal Muscular Atrophy due to homozygous deletion of exon 7 in SMN1	SMA	2019
		X-linked Adrenoleukodystrophy	X-ALD	2019
	, of	Critical Congenital Heart Disease	ССНД	2014
	Point Care	Hearing Loss -Congenital Octomegalovirus	HEAR -cCMV	2014
		congenitar of tonicgalorinas		2027

<sup>1</sup>Projected screening start year is 2025.

DPH 11/2024

## **10.2 REFERENCES**

CLSI. Dried Blood Spot Specimen Collection for Newborn Screening. 7th ed. CLSI standard NBS01. Clinical and Laboratory Standards Institute; 2021.

CLSI. Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns. 2<sup>nd</sup> ed. CLSI guideline NBS03. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.

Oster ME, Pinto NM, Pramanik AK, et al; American Academy of Pediatrics, Section on Cardiology and Cardiac Surgery, Section on Hospital Medicine, Committee on Fetus and Newborn. Newborn Screening for Critical Congenital Heart Disease: A New Algorithm and Other Updated Recommendations: Clinical Report. Pediatrics. 2025;155(1): e2024069667

JUSTIA Company. 2014 Georgia Code Title 31 – Health Chapter 1 - General Provisions; Access to Eye Care Article 1 – General Provisions § 31-1-3.2 - Hearing screenings for newborns https://law.justia.com/codes/georgia/2014/title-31/chapter-1/article-1/section-31-1-3.2

JUSTIA Company. 2022 Georgia Code Title 31 – Health Chapter 1 – General Provisions § 31-1-3.2 - Hearing screenings for Newborns

Georgia Code Title 21 – Hearing Screenings for Newborns

## 10.3 POLICY REVISIONS RECORD

#### **Policy Revisions Record**

#### **Georgia Newborn Screening Policy and Procedure Manual 2025**

REVISION DATE	SECTION & PAGE	<b>REVISION DESCRIPTION</b>	REVISION TYPE A=Added D=Deleted M=Modified	<b>CITATION</b> Revision required by Regulation, Legislation, etc.
6/18/2024	Page 4	Corrected Appendix O title. Changed from "Newborn Hearing Screening Results and Recommendations Form" to "Newborn Screen Correction Form".	М	N/A
6/18/2024	Page 22; Table Code 21	Corrected "Bood" typo. Updated to "Blood".	М	N/A
6/18/2024	Page 59	Corrected Appendix O title. Changed from "Newborn Hearing Screening Results and Recommendations Form" to "Newborn Screen Correction Form".	М	N/A
9/23/2024	Page 18	Clarified that the transfusion protocol is only applicable when the DBS schedule is interrupted.	М	N/A
9/23/2024	Page 21	Changed >7 days after the date of collection to >10 days after the date of collection. The >10 days aligns with Georgia Code.	М	N/A
9/23/2024	Page 30	Added overview of required cCMV testing for all infants who fail their final hearing screening prior to 21 days of age or before discharge, whichever one comes first. Added link to cCMV policy and procedure manual for further information.	A	In accordance with Georgia Code Section 31-5-1, amendments take effect on October 10, 2024. http://dph.georgia.g ov/regulationsrule- making
9/23/2024	Page 58; Appendix N	Replaced "Newborn Hearing Screening Results and Recommendations Form" with updated version.	М	N/A
9/23/2024	Page 49; Appendix G-2	Replaced "Newborn Screening Guidance for the Well-Baby Nursery Algorithm" with updated version.	М	N/A

REVISION DATE	SECTION & PAGE	<b>REVISION DESCRIPTION</b>	REVISION TYPE A=Added D=Deleted M=Modified	<b>CITATION</b> Revision required by Regulation, Legislation, etc.
9/23/2024	Page 50; Appendix G-3	Replaced "Newborn Screening Guidance for Infants Admitted into a NICU or SCBU Algorithm" with updated version.	Μ	N/A
11/13/2024	Page 60; Appendix P	Added "Newborn Screening Panel Legislative and Regulatory History" document.	А	N/A
12/3/2024	Section 5.4, page 18	Modified titling and moved introduction to be found under Low Birth Weight Infants section.	М	N/A
12/3/2024	Section 5.4, page 18	Added clarification about the DBS schedule in the Transfusions/ Blood Products/ECMO section.	A	N/A
12/3/2024	Section 5.4, page 18	Modified/clarified Parenteral Nutrition section.	М	N/A
12/3/2024	Section 5.4, Page 19	Added section titled NPO/IV Fluids Only to clarify timing of screening for this population.	А	N/A
12/3/2024	Section 5.4, Page 19	Modified Older Infants/Children section for clarity.	М	N/A
12/3/2024	Section 7.5, page 27	Modified titling to include NICU/SCBU and Prenatal CCHD Diagnosis to address screening guidelines.	M/A	N/A
12/3/2024	Section 9.2, Page 34	Modified wording in transfusion section for clarity; added Abnormal Hgb Results for Transfused Infants section per recommendation of Hemoglobin Committee.	M/A	N/A
12/3/2024	Section 4.2, page 13	Modified verbiage describing "meconium ileus".	Ν	N/A
12/17/2024	Section 7.2, page 25	Modified the Revised Algorithm for Critical Congenital Heart Disease (CCHD) Screening with Pulse Oximetry with the AAP's 12/16/2024 recommended algorithm.	M/A	N/A
12/17/2024	Section 7.1, page 23	Modified/ added note regarding the use of CCHD as a screening tool.	M/A	Updated 2024 AAP CCHD Protocol
12/17/2024	Section 7.5, page 27	Modified/added specific NICU/SBCU guidelines to align with new protocol.	M/A	Updated 2024 AAP CCHD Protocol

